

# EYE, RETINA, AND VISUAL SYSTEM OF THE MOUSE

Edited by Leo M. Chalupa and Robert W. Williams

THE MIT PRESS  
CAMBRIDGE, MASSACHUSETTS  
LONDON, ENGLAND

© 2008 Massachusetts Institute of Technology

All rights reserved. No part of this book may be reproduced in any form by any electronic or mechanical means (including photocopying, recording, or information storage and retrieval) without permission in writing from the publisher.

For information about special quantity discounts, please email [special\\_sales@mitpress.mit.edu](mailto:special_sales@mitpress.mit.edu)

This book was set in Baskerville by SNP Best-set Typesetter Ltd., Hong Kong.

Printed and bound in the United States of America.

Library of Congress Cataloging-in-Publication Data

Eye, retina, and visual system of the mouse / Leo M. Chalupa and Robert W. Williams, editors.

p. cm.

Includes bibliographical references and index.

ISBN 978-0-262-03381-7 (hardcover : alk. paper)

1. Mice—Sense organs. 2. Eye. 3. Visual pathways.

I. Chalupa, Leo M. II. Williams, Robert W., 1952–

QL737.R6E94 2008

573.8'819353—dc22

2007047445

10 9 8 7 6 5 4 3 2 1

# INDEX

Note: Page numbers followed by *f* indicate figures; page numbers followed by *t* indicate tables.

## A

- A and A/J strain  
  auditory evoked brainstem response in, 22  
  conditioned taste aversion in, 29  
  hearing and visual abilities in, 15t, 16  
  mutation and effect in, 62t  
  pattern discrimination in, 18  
  taste ability in, 24  
  visual acuity of, 20  
*ABCA4* mutations, 723  
*Abca4/Abcr* null mutant mice, Stargardt  
  macular degeneration in, 540–542,  
  541f  
Ablation, targeted, to assess role of  
  photoreceptors, 595–596  
ab-LIM, directed growth of retinal ganglion  
  cell axons toward optic disc and, 384  
AC Master, 78, 78f  
*Acanthamoeba* infections, 508–509  
 $\alpha$ A/CAT transgenic mice, 273  
Achromatopsia, gene replacement therapy  
  for, 612–613  
Acoustic startle test, 22  
Adenoassociated virus (AAV) gene therapy,  
  605–614  
  antiangiogenic, 607  
  for choroidal neovascularization, 610  
  future directions for, 613–614  
  gene replacement strategies and, 610–613  
  for functional defects in retina, 611–613  
  for structural defects in retinal disease,  
  610–611  
  for retinal neovascularization, 607,  
  609–610  
  vectors for, 605–607, 606t, 608t–609t  
Advanced glycation end products (AGEs),  
  diabetic retinopathy and, 552  
African pygmy mice, 3, 5, 8  
Age-related eye diseases, 581–588  
  cataracts as, in human and mouse eyes,  
  588  
  in mice, search for, 581–582, 583t–584t  
  mouse models for, 581  
Age-related macular degeneration (AMD)  
  gene therapy for, 607  
  in human and mouse eyes, 582, 584–588  
Age-related retinal degeneration (ARRD), in  
  human and mouse eyes, 582,  
  584–588, 585f–587f, 585t  
Akita mice, diabetes in, 549  
  retinal neurodegeneration induced by, 551  
AKR/J strain  
  auditory evoked brainstem response in,  
  22  
  hearing and visual abilities in, 15t, 16  
  pattern discrimination in, 18  
  taste ability in, 23  
  visual acuity of, 20  
Albinism, retinal ganglion cell projections  
  and, 397  
Albino mice, 61  
  pattern discrimination in, 18  
  visual acuity of, 20  
Aldose reductase, diabetic retinopathy and,  
  552  
Alleles. *See also specific alleles*  
  defining disease progression, clinical  
  outcome, or important domains,  
  650  
  defining response to treatment, 651  
  defining responses to environmental  
  influences, 650–651  
  phenotypic variation due to, 649–651  
Allen Brain Atlas, search of, for RALDH3  
  colocalized genes, 370–371, 372f  
All-*trans*-retinol dehydrogenase, in visual  
  cycle, 722–723  
Amacrine cells  
  cholinergic (starburst)  
  mosaic architecture of, 150–151, 151f  
  study approaches for, 598  
  dopaminergic  
  genetic labeling of, 597–598  
  mosaic architecture of, 151–153  
  gap junctions of, 167  
  glucagon, in mouse versus chicken eye,  
  82–83  
  transgenic mice for study of, 597–598  
  V-amacrine, 597  
AMPA, excitatory lateral geniculate nucleus  
  responses and, 420, 422  
AMPA receptors (AMPArs), 223–225  
  long-term depression and, 470  
  in reticulogeniculate synapses, 431, 439  
Anaphase-promoting complex (APC), retinal  
  ganglion cell axon growth ability and,  
  408  
Anesthesia dolorosa, model of, 25  
Angioblasts, 285  
Angiogenesis, 285–286, 639–641  
  hyaloid vessel regression versus, in norrin  
  deficient mice, 532, 533f  
  sprouting, failure in, in norrin deficient  
  mice, 531–532  
  VEGF-A in, 640–641  
Angiopoietin, diabetic retinopathy and,  
  552–553  
Angiopoietin/Tek system, retinal  
  vascularization and, 292  
Angiostatin, anti-angiogenic properties of,  
  610  
Angular vestibulo-ocular reflex (aVOR),  
  88–91, 89f, 90f  
  gain and response axis of, adaptation of,  
  96–98, 97t  
Anophthalmic mice, 269, 271  
Anterior chamber, cell types in, 644–645  
Anterior chamber–associated immune  
  deviation (ACAID), 521–522  
  pigmentary glaucoma and, 483  
Antiangiogenic gene therapy, 607  
Antibodies, against neurofilament H, as  
  retinal ganglion cell marker, 193  
Antigen-presenting cells (APCs),  
  experimental autoimmune uveitis  
  and, 519  
Anxiety-related behavior tasks, 29  
API, in cornea and lens development, 703  
AP2, in cornea and lens development, 703  
*AP2 $\alpha$* , lens development and, 277  
*AP2 $\alpha$ -Cre* mice, 275  
Apo-cellular RBP (CRALBP), 724  
Apoptosis. *See* Cell death  
Aquaporin, cataracts and, 495  
Aqueous humor  
  inflow of, 129, 129f  
  outflow of, 129–131  
  uveoscleral, 132–133  
Astrocyte(s)  
  in optic nerve, 201–202, 202f  
  retinal vascularization and, 287  
Astrocyte progenitor cells (APCs), 390,  
  390f  
Atoh7, retinal ganglion cell development  
  and, 194  
ATP-binding cassette A4, in visual cycle,  
  723  
Atropine, myopia development and, 83  
Auditory evoked brainstem response (ABR),  
  20, 22  
Autism spectrum disorders, visual cortical  
  functions in, 245  
Autoimmune uveitis. *See* Experimental  
  autoimmune uveitis (EAU)  
Automated visual responses, measures of,  
  111–115, 114f, 115f  
Avoidance conditioning, active and passive,  
  27–28  
a-waves, cone, 138  
Axial length, changes in, measurement,  
  77–79, 78f  
Axons, of retinal ganglion cells. *See* Retinal  
  ganglion cells (RGCs)

## B

- Bacterial artificial chromosome (BAC)  
  transgenesis, 594, 594f  
Bacterial infections, 506–508  
Bagg, Halsey J., 13

- BALB strains, 62t
- BALB/c
- anxiety-related behavior tasks and, 29
  - auditory evoked brainstem response in, 22
  - conditioned odor preference in, 28
  - learning and memory in, 27
  - pain sensitivity in, 25
  - photoreceptor response damage by light and, 575, 577
- BALB/cByJ
- hearing and visual abilities in, 15t, 16
  - pattern discrimination in, 18
  - visual acuity of, 20
- BALB/cJ
- conditioned taste aversion in, 29
  - hearing and visual abilities in, 15t, 16
  - pain sensitivity in, 25
  - pattern discrimination in, 18
  - visual acuity of, 20
- Barnes maze, 27
- Basic fibroblast growth factor (bFGF), retinal ganglion cell axon growth and, 401
- Batten disease, 612
- Bcl-2
- Bcl-2*-overexpressing retina, 152
  - cell death and, 337f, 337–338
  - retinal neovascularization and, 293
- Beaded filaments, 499
- Behavior, environmental enrichment and, 450
- Behavioral studies of mouse vision, 107–116
- applied measurement of, 115–116, 116f
  - idiosyncrasies associated with whole animal behavior and, 108–109
  - measures of, 109–115
  - of automated visual responses, 111–115, 114f, 115f
  - of visual perception in reinforcement-based tasks, 109–111, 111f–113f
  - rationale for, 107–108
- Behavioral tasks, for sensory function
- measurement, 15t, 15–16
  - future directions for use of, 30
  - of hearing, 20, 22
  - learning and measurement tasks and, 25–29
  - of olfaction, 22–23
  - of pain sensitivity, 24–25
  - of tactile and vibrissae sensitivity, 24
  - of taste, 23–24
  - of vision, 16–20
- BEN, directed growth of retinal ganglion cell axons toward optic disc and, 382–383
- Bfsp1*, cataracts and, 499
- Bfsp2*, cataracts and, 499
- bHLH transcription factors, retinal development and, 303
- BH3-only protein, cell death and, 338
- Binocularity, in primary visual cortex, 49–51, 50f
- transcallosal cells and, 50–51
- Bipolar cells
- Clomeleon in, 597
  - depolarizing, 136
  - synaptic transmission in outer retina and, 176f, 176–179, 177t
  - gap junctions of, 167
  - hyperpolarizing, 136
  - synaptic transmission in outer retina and, 176f, 176–179, 177t
  - ON and OFF pathway segregation and, 353–354, 357
  - in *Rb*-deficient retinas, 315
  - role of gap junctions in, transgenic mice to study, 596–597
  - synaptic output of, control by GABA<sub>C</sub>R-mediated inhibition, 182–183
- Birdshot retinochoroidopathy, 516
- Blind-sterile* mutant, 501
- Bmp4*, lens development and, 276
- Bmp7*, lens development and, 276
- Bone morphogenic protein (BMP) receptor 1b, targeting of retinal ganglion cell axons to optic disc and exit from eye and, 385
- Brain
- electroporation and, 626
  - environmental enrichment and, 450
  - retinoic acid actions in, 364–365
- Brain Gene Expression Map (BGEM), search of, for RALDH3 colocalized genes, 370
- Brain-derived neurotrophic factor (BDNF)
- acceleration of visual system development and, environmental enrichment compared with, 453, 454
  - cell death and, 336
  - environmental enrichment and, increase due to, 457–458
  - retinal ganglion cell axon growth and, 401
- Brief-access taste test, 24
- Brightness detection, measurement of, 16, 17f, 18
- Brn-3b, chiasm patterning and, 396–397
- Brn-3b*<sup>-/-</sup> mice, retinal ganglion cell axon growth ability and, 407–408
- Brn-3b*<sup>-/-</sup> *Brn-3c*<sup>-/-</sup> mice, retinal ganglion cell axon growth ability and, 407–408
- Brn-3c, chiasm patterning and, 397
- Brn-3.2, directed growth of retinal ganglion cell axons toward optic disc and, 383–384
- Bruch's membrane, plate 64
- BUB strain, mutation and effect in, 62t
- BUB/BnJ
- auditory evoked brainstem response in, 22
  - taste ability in, 23
- Buried food test, 22
- b-waves, cone-driven, 137, 137f
- BXD Genetic Reference Panel of Mice, 664–665, 666t, 667
- BXSB strain, pattern discrimination in, 18
- ## C
- C strain, 13
- Cacna1a* mutations, 100–101
- CaCna1f*<sup>cmh2</sup> mice, retinal ganglion cell responses in, 179–181, 180f
- Cadherin4, retinal vascularization and, 287
- Calcium
- retinal ganglion cell axon growth ability and, 408
  - synaptic transmission in outer retina and, 177–178
- Calcium currents, in dorsolateral geniculate nucleus, 220
- Calcium imaging
- of direction-selective retinal ganglion cell responses, 598
  - for retinal wave measurement, 343
  - with two-photon microscopy, for ocular dominance plasticity assessment, 441–442, 442f
- Calmodulin kinases (CaMKs), retinal ganglion cell axon growth ability and, 408
- cAMP, retinal ganglion cell axon growth ability and, 408
- cAMP response element-binding protein (CREB), retinoic acid and, 366
- Candida albicans* infections, 508
- Capecchi, Mario R., 35
- Carbohydrates, protein-bound, cataracts and, 499–500
- Carrageenan, subcutaneous injections of, 25
- Caspases, cell death and, 338
- CAST/Ei strain, taste ability in, 23
- CAST/Eij
- hearing and visual abilities in, 15t
  - pattern discrimination in, 18
- Cat3*, 501
- Cat5*, 501
- Cataracts
- age-related, in human and mouse eyes, 588
  - gene expression leading to formation of, 273
  - genetics of, 493–501
  - mouse models for metabolic cataracts and, 499–500
  - mouse models for senile cataracts and, 500
  - mutations affecting lens membranes and, 495–496
  - mutations affecting structural proteins of lens and, 496–499
  - mutations at early stages of lens development and, 493–494, 494f
  - pattern electroretinography and, 124
- β-Catenin, inhibition of lens induction by, 277–278
- Caviness, Vernon, 245
- CBA strains, 13
- avoidance learning in, 28
- CBA/Ca, anxiety-related behavior tasks and, 29
- CBA/Caj, auditory evoked brainstem response in, 22
- CBA/J
- cued and contextual fear conditioning in, 27
  - learning and memory in, 26, 27
  - tactile sensitivity in, 24
  - taste ability in, 23

- CBA strains (continued)  
 learning and memory in, 27  
 mutation and effect in, 62t  
 C57BL/6 and C57BL/6J strain,  
 271–272  
 anxiety-related behavior tasks and, 29  
 auditory evoked brainstem response in,  
 22  
 circadian photoentrainment and, 210  
 conditioned odor preference in, 28  
 cones of, anatomy of, 135–137  
 diabetes-induced retinal  
 neurodegeneration in, 551  
 hearing and visual abilities in, 15t, 16  
 learning and memory in, 27  
 mutation and effect in, 62t  
 olfactory ability in, 22, 23  
 pain sensitivity in, 25  
 pattern discrimination in, 18  
 as standard strain, 62  
 tactile sensitivity in, 24  
 taste ability in, 23, 24  
 visual acuity of, 20  
 C57BL/6NCrlBR strain  
 conditioned odor preference in, 28  
 pattern discrimination in, 18  
 C57BL/10 strain, 271–272  
 C57BR/cdJ strain, auditory evoked  
 brainstem response in, 22  
 CCCTC binding factor, eye field  
 transcription factor regulation by,  
 301  
 CCL2 protein, cell death inhibition by, 122,  
 123f  
 CD-1 outbred strain  
 conditioned odor preference in, 28  
 olfactory ability in, 22, 23  
 pattern discrimination in, 18  
 CD18, diabetic retinopathy and, 553  
 Cell adhesion molecules (CAMs), retinal  
 ganglion cell axon guidance through  
 visual pathway and, 393  
 Cell cycle progression, in retinal progenitor  
 cells, *Math5* and, 324  
 Cell death  
 of developmental cells, retinal ganglion  
 cells and, 122  
 of endothelial cells, oxygen-induced  
 retinopathy and, 293  
 of horizontal cells, 149  
 in mouse retina, 333–339  
 contribution to shaping of retinofugal  
 and retinal circuits, 334–336, 335f  
 major phases of, 333–334, 334f  
 molecules involved in signaling,  
 regulating, and executing, 336–339,  
 337f  
 neurotrophic hypothesis of, 336  
 of retinal ganglion cells, 333, 334  
 in glaucoma, 485–487, 487f, plate 33,  
 plate 34  
 matching sizes of interconnected  
 neuronal populations and, 335,  
 335f  
 molecules involved in signaling,  
 regulating, and executing, 337, 338  
 Cell type-specific promoters  
 lineage tracing in retina using, plate 60  
 multicolor labeling of retina using, plate  
 59  
 spatial regulation of gene expression using,  
 plate 58  
 Cell-labeling techniques, for study of retinal  
 ganglion cells, 599  
 Cellular retinaldehyde-binding protein  
 (CRALBP), in visual cycle, 726  
 Cellular retinol-binding protein type 1  
 (CRBP1), in visual cycle, 725  
 Central nervous system. *See also* Brain  
 plasticity of, pattern electroretinographic  
 measurement of, 121–122  
 Central retinal artery (CRA), anatomy of,  
 203–204, 204f  
 Central retinal vein, anatomy of, 204  
 Centrifugal model of evolution, 6, 7f  
 cGMP, retinal ganglion cell axon growth  
 ability and, 408  
 C3H strains, 13  
 avoidance learning in, 28  
 conditioned taste aversion in, 29  
 mutation and effect in, 62t  
 C3HeB/FeJ strain, visual acuity of, 20  
 C3H/HeJ strain, cued and contextual fear  
 conditioning in, 27  
 C3H/He and C3H/HeJ strain  
 anxiety-related behavior tasks and, 29  
 auditory evoked brainstem response in, 22  
 hearing and visual abilities in, 15t, 16  
 learning and memory in, 26, 27  
 pain sensitivity in, 25  
 pattern discrimination in, 18  
 tactile sensitivity in, 24  
 taste ability in, 23  
 visual acuity of, 20  
 Chase, Herman, 269  
 Chemical nociception, measurement of, 25  
 CHI strain, 13  
*Chlamydia trachomatis* infections, 508  
 Cholera toxin  $\beta$  subunit (CTB), development  
 of eye-specific segregation in lateral  
 geniculate nucleus and, 418  
 Cholesterol metabolism, cataracts and, 500  
 Cholinergic amacrine cells  
 mosaic architecture of, 150–151, 151f  
 study approaches for, 598  
 Chondroitin sulfate proteoglycans (CSPGs)  
 control of initial retinal ganglion cell axon  
 outgrowth polarity and, 381  
 ocular dominance plasticity and, 454–455  
 Chorionicapillaris, plate 64  
 Choroidal circulation, oxygen delivery to  
 retina and, 560–561  
 Choroidal neovascularization, gene therapy  
 for, 610  
 Chromatin, rod development and, 317  
 Chronology of mouse visual system  
 development, 257–264  
 comparison with development in rhesus  
 macaque, 261  
 future research directions for, 264  
 human developmental timing versus,  
 261–262, 262f  
 model for, 257, 258t, 259, 259f, 260f  
 individual variation and observational  
 error and, 260–261  
 technical and qualitative evaluation of  
 model's predictions and, 259–261  
 mouse models for, 262–263  
 scaling of eye and cortex and, 263–264  
 variability of mouse strains and, 262  
 Chung peripheral nerve injury model, 25  
 Chx10, retinal development and, 303  
*Chx10-Cre;Rb<sup>Lux/-</sup>* mice  
 retinal synaptogenesis in, 317–318, 318f  
 rod development in, 313–314  
*Chx10-Cre;Rb<sup>Lux/+</sup>* mice, retinal synaptogenesis  
 in, 317  
*Chx10-Cre;Rb<sup>Lux/Lux</sup>* mice, rod development in,  
 314  
*Chx10-Cre;Rb<sup>Lux/Lux</sup>;Z/AP* mice, rod  
 development in, 315  
 C12I strain, 13  
 Ciliary body, position of, aqueous humor  
 outflow and, 129  
 Ciliary epithelium  
 nonpigmented, 129  
 structure of, 129  
 Ciliary muscle, 129  
 Ciliary neurotrophic factor (CNTF), 613  
 retinal ganglion cell axon growth and,  
 401  
 Ciliary processes, 129, 130f  
 Circadian behavior, mouse models for, 215  
 Circadian photoentrainment, 207–215  
 circadian behaviors in mice and, 207–209,  
 208f  
 circadian photoentrainment pathway  
 neuroanatomy and, 209–210  
 intrinsically sensitive retinal ganglion cells  
 and, 211–212  
 morphology, ontogeny, and functional  
 diversity of, 211–212, 212f  
 melanopsin and, 213–214  
 phototransduction mechanism and,  
 213–214  
 melanopsin-expressing retinal ganglion  
 cell role in circadian  
 photoentrainment and, 210–211  
 molecular basis of, 214f, 214–215  
 mouse as model system for human  
 circadian rhythm and, 207  
 photosensitivity and, 209  
 target brain regions innervated by  
 intrinsically photosensitive retinal  
 ganglion cells and, 212f, 212–213  
 C57L/J strain, auditory evoked brainstem  
 response in, 22  
 C58/J strain, tactile sensitivity in, 24  
*Clock* gene, 65  
 Clomeleon, in bipolar cells, 597  
 Cloning of genetic modifiers, 653–655  
 chromosomal localization of modified  
 traits and, 653–654  
 gene expression profiling and, 654–655  
 haplotype analysis and, 654  
 microarray analysis and, 654–655  
 modifier screens using mutagenesis and,  
 655

- Cloning of genetic modifiers (continued)  
 segregating crosses with multiple strains and, 654
- c-Maf*, lens fiber differentiation and, 278
- Coats' disease, 528
- Cochlear vasculature, abnormalities of, in *Ndph* knockout mice, 533–534
- Cognitive functions, higher order, vision in tasks evaluating, 25
- Collagen I, primary open-angle glaucoma and, 482
- Color blindness, gene replacement therapy for, 612–613
- Commensal mice, 5
- Compensatory eye movements, 87, 88  
 adaptive properties of, 96–99, 97t, 98f, 99f, 100
- Complete Freund's adjuvant (CFA), experimental autoimmune uveitis induced by, 515, 520
- Conditioned odor preference, 28
- Conditioned taste aversion, 28–29
- Cone(s), 135–144. *See also* Photoreceptors  
 anatomy of, 135–137  
 numerosity and retinal disposition and, 135–136, 136f, plate 2  
 retinal connectivity of cones and, 136  
 S- and M-opsins and, 136–137  
 ultrastructure and, 136  
 damaging of, by rod dysfunction, 566  
 dim-flash responses of, plate 3  
 electroretinographic studies of, 137–139  
 a-wave and, 138  
 b-wave and, 137, 137f  
 functional coexpression of S- and M-opsins and, 138–139  
 phenotypes of mice with cone phototransduction genes inactivated and, 138, 138f  
 rapid recovery from bleaching stimuli and, 138  
 functions of, 135  
 gap junctions of, 165–166, 166f  
 of mouse compared to other mammalian species, 36  
*Nrl<sup>-/-</sup>*, 139, 141–144  
 caveats for investigations of, 142  
 electrophysiological recordings and, 141–142, 143f  
 histochemical and ultrastructural evidence and, 141, 142t  
 prospects for studies using, 143–144  
 role in scotopic visual pathway, targeted ablation to assess, 595–596  
 scaling of, 263  
 single-cell recordings and, 139, 140f–142f  
 spatial vision and, 81–82
- Cone pedicles, 136
- Cone synapses, 136
- Cone visual cycle, 727, 728f, plate 69
- Congenital stationary night blindness (CSNB), 650
- Connective tissue, in optic nerve, 202, 203f
- Connexins  
 in lens, cataracts and, 495–496, 496f  
 as retinal ganglion cell markers, 193
- retinal gap junctions and, 165  
 of amacrine cells, 167  
 of bipolar cells, 167  
 of ganglion cells, 169, 171  
 of horizontal cells, 167  
 of photoreceptors, 165–166  
 in proximal rod pathways, 167–169, 168f
- retinal waves and, 347
- Cornea  
 development of, 697, 698f  
 transcription factors involved in, 699f, 699–703, plate 66  
 gene expression in. *See* Gene expression, in cornea and lens  
 neovascularization of, matrix metalloproteinase-9 and, 506  
 refractive power of, 73
- Corpus callosum, visual cortex connections with, 46–47, 47f
- Coulombre, Alfred and Jane, 269
- Cre expression, in Le-Cre, MLR10, and MLR39 strains, plate 12
- Cre recombinases  
 cell type-specific regulation using, 626–627, 629, 630f  
 conditional gene alterations using, 274–275, 275f  
 conditional RNAi and, 629–630, 632f  
 temporal and cell-type specific regulation using, 629, 631f  
 temporal regulation using, 626, 627f, plate 57
- Cre-lox recombinase system  
 for drug-controlled gene expression, 600f, 600–601  
 for site-specific recombination, 599–600
- Cre-lox-P system, 274
- Critical periods, experience-dependent plasticity and, 473
- Cross-axis adaptation, 98–99, 99f
- Crx*, rod development and, 316
- Cry*, circadian photoentrainment and, 214, 214f
- Cry<sup>-/-</sup>* mice, circadian photoentrainment and, 215
- Cry<sup>-2</sup>* mice, circadian photoentrainment and, 215
- Cryaa*  
 cataracts and, 496, 496f, 588  
 mutations of, plate 37
- Cryab*, cataracts and, 496
- Crybal*, cataracts and, 497
- CRYBB2*, cataracts and, 497
- Crybb2*, cataracts and, 497
- Cryg*  
 cataracts and, 497–498, 498f  
 mutations of, plate 38
- CRYGC*, cataracts and, 498
- CRYGD*, cataracts and, 498
- CRYGD-P23T* mutation, cataracts and, 498
- Crystallins  
 expression in cornea, 705  
 in lens, 703–704, 704f, 711–713, 716, 716f  
 posttranslational modification of, 715, 716  
 lens development and, 272
- $\alpha$ -Crystallins  
 $\alpha$ A-crystallin structure and, plate 67  
 cataracts and, 496, 496f  
 expression in lens, 703–704, 712f, 712–713
- $\beta$ -Crystallins  
 cataracts and, 497  
 expression in lens, 704, 713
- $\tau$ -Crystallins  
 cataracts and, 497–498, 498f  
 expression in lens, 704, 713
- Cued and contextual fear conditioning, 27
- Cued platform task, for measuring visual perception, 110
- Curare, retinal wave blocking by, 345
- Current-clamp recordings, for retinal wave measurement, 343
- Cx36 expression, by photoreceptors, plate 5
- Cyclooxygenase-2 (COX-2) inhibitors, herpes simplex virus infection and, 506
- CYP1B1*  
 primary congenital glaucoma and, 483  
 primary open-angle glaucoma and, 482
- Cytomegalovirus infections, murine, 509
- Cytoskeletal proteins, cataracts and, 498–499

## D

- DBA/2HaSnm strain, auditory evoked brainstem response in, 22
- DBA, DBA/2, and DBA/2J strain, 13  
 anxiety-related behavior tasks and, 29  
 auditory evoked brainstem response in, 22  
 conditioned odor preference in, 28  
 cued and contextual fear conditioning in, 27  
 as glaucoma model, pattern electroretinogram application in, 122–124, 123f  
 hearing and visual abilities in, 15t, 16  
 learning and memory in, 27  
 mutation and effect in, 62t  
 pain sensitivity in, 25  
 pattern discrimination in, 18  
 pigment dispersion syndrome in, 483–485, 484f  
 melanosome contribution to, plate 32  
 tactile sensitivity in, 24  
 taste ability in, 24  
 visual acuity of, 20
- DBA/2NCr1BR strain  
 conditioned odor preference in, 28  
 pattern discrimination in, 18
- db/db mice  
 diabetes in, 550  
 diabetes-induced retinal neurodegeneration in, 551
- Delayed-type hypersensitivity (DTH) responses, 505

- Dendritic arborization, Cre-lox recombinase system for study of, 601
- Dendritic cells, antigen-pulsed, experimental autoimmune uveitis induced by injection of, 516
- Dendritic outgrowth, of horizontal cells, 150, 150f
- Depolarizing bipolar cells (DBC), 136 synaptic transmission in outer retina and, 176f, 176–179, 177t
- Depth of field, measurements of, 80, 80f
- Developmental glaucoma, 483
- Diabetes, adherence in retinal microvasculature of diabetic mouse, plate 47
- Diabetic retinopathy, 547–554 biochemical changes in mouse retinal contributing to development of, 551–553, 552f in humans, 547 in mice, 547–548, 548f nonproliferative, mouse models of vascular lesions of, 548–551 chemically induced diabetes and, 548–549, 549f nondiabetic, developing diabetic-like retinopathy, 550–551 spontaneous diabetes and, 549–550 nonproliferative stage of, 547 proliferative, mouse models of, 553–554 insulin-like growth factor-1 and, 554 oxygen-induced retinopathy and, 553–554 VEGF overexpression and, 554 proliferative stage of, 547 retinal neurodegeneration and, mouse models for study of, 551
- Dickkopf1, eye field formation and, 301
- Diffusers, deprivation myopia from, 82
- Dopaminergic amacrine cells genetic labeling of, 597–598 mosaic architecture of, 151–153
- Dorsal terminal nuclei (DTN), retinal projections to, 41
- Dorsal visual stream, 373f, 373–374
- Dorsolateral geniculate nucleus (dLGN), 219–229 intrinsic physiology of neurons of, 219–221 calcium currents and, 220 hyperpolarization-activated currents and, 221 oscillations and, 221 potassium currents and, 220–221 sodium currents and, 220, 220t modulation of retinal signal by, 225–228 burst and tonic responses and, 227–228, 228f of intrinsic thalamocortical relay cell physiology, 226–227 local geniculate inhibition and, 225–226, 226f presynaptic, 225 output of, 221–225 retinogeniculate inputs and spatial information and, 221–223, 222f–224f retinogeniculate inputs and temporal information and, 223–225 retinal projections to, 40, 44–45
- Dräger, Ursula, 245
- Drug-controlled gene expression Cre-lox recombinase system for study of, 600f, 600–601 reversible, 601
- ## E
- Early-life stimulation, neuronal and behavioral development and, 450–451 *Efnb2*, retinal vascularization and, 288 *Egr-1* knockout, refractive errors in, 83 *Egr-1* mRNA, regulation of, 82 Eicosanoids, diabetic retinopathy and, 553
- Eight-arm radial maze, 18
- Electrical stimulation, retinal ganglion cell axon growth and, 404–405
- Electroporation, 621–631 controlling expression following, 626–630 cell type-specific regulation using specific promoters and, 626–627, 628t, 628f–630f, 629 conditional RNAi and, 629–630, 632f temporal and cell type-specific regulation and, 629, 631f temporal regulation and, 626, 627f future applications of, 630–631 method of, 621–626 in vitro, retinal, 623, 625f, 625–626, plate 55, plate 56 in vivo, comparison to other in vivo gene delivery methods, 621 in vivo, brain, 626 in vivo, retinal, 621–623, 622f–624f, plate 50, plate 51, plate 52, plate 53, plate 54
- Electroretinogram (ERG) with cone phototransduction gene inactivation, 138, 138f functional features of cones and, 138, 138f
- Elevated plus maze, 29
- Elevated zero maze, 29
- ELOVL4* gene, age-related eye diseases and, 582, 584–588
- ELOVL4* mice, 613, 638
- Embryonic stem cells, in vitro generation of retinal ganglion cells from, 329–330
- Encephalitis, viral, 509
- Endostatin, anti-angiogenic properties of, 610
- Endothelial cells, apoptosis of, oxygen-induced retinopathy and, 293
- Endothelial tip cell guidance, retinal vascularization and, 287
- Endotoxin-induced uveitis (EIU), 513–515, 514f histology of, plate 39
- Environmental enrichment plasticity and, 449–459 early-life stimulation effects on neuronal and behavioral development and, 450–451 neural consequences of environmental enrichment and, 450 visual system development and, 451–459, 452f, 454f, 455f, 457f, 459f, plate 28, plate 29, plate 30 temporal phases during development controlled by environmental richness and, 458, 459f
- Enzyme replacement therapy, 639
- EphB2, targeting of retinal ganglion cell axons to optic disc and exit from eye and, 383f, 383–385
- EphB3, targeting of retinal ganglion cell axons to optic disc and exit from eye and, 383f, 383–385
- Ephb4*, retinal vascularization and, 288
- Ephrin(s), targeting of retinal ganglion cell axons to optic disc and exit from eye and, 383f, 383–385
- Ephrin ligands, retinal vascularization and, 288
- Ephrin-B1/ephrin-B2, retinal ganglion cell axon divergence at chiasm and, 393, 394f, 395
- Erythropoietin, proliferative retinopathy and, 292–293
- Esi-1/Elf3, in cornea and lens development, 703
- Ethylnitrosourea (ENU), as mutagenic agent, 493
- Evans, Martin J., 35
- Evolution centrifugal model of, 6, 7f of house mice, 6–8, 7f sequential (linear) model of, 6–7, 7f
- Excitatory postsynaptic potentials (EPSPs), in lateral geniculate nucleus, 420, 421f, 422, 424
- Experience-dependent visual cortical plasticity, 465–473 adult ocular dominance plasticity and, 472–473, 474f mechanisms of ocular dominance shift in mice and, 468–471 monocular deprivation in juvenile mice and, 463, 469f, 470f stimulus-selective response potentiation and, 471–472, 472f visually evoked potential recording technique and, 466, 467f, 468
- Experimental autoimmune uveitis (EAU) associated with anti-tumor response to melanoma antigen, 517 histology of, plate 39 in human lymphocyte antigen transgenic mice, 516 induced by active immunization with retinal antigen, 515, 516t, 517f induced by adoptive transfer of antigen-specific T cells, 515 induced by injection of antigen-pulsed dendritic cells, 516

- Experimental autoimmune uveitis  
(continued)  
in mice expressing a transgenic target antigen in the retina, 515–516  
pathogenesis of, critical checkpoints in, plate 39  
spontaneous, 516–517
- Expressed sequence tags (ESTs), 662–663
- ey1 mutation, 269
- ey2 modifier genes, 269
- Eye, of mouse compared to other mammalian species, 35
- Eye field transcription factors (EFTFs), 299–302  
expression in retinal progenitor cells, 299, 302–303  
interaction of, 300  
regulation of, 300–301  
transcription targets of, 301–302
- Eye movements, 87–102  
after-nystagmus and velocity storage integrator and, 94–96, 96f  
angular vestibulo-ocular reflex and, 88–91, 89f, 90f  
compensatory, 87, 88  
adaptive properties of, 96–99, 97t, 98f, 99f  
control of, importance of, 87  
in foveate and avfoveate mammals, 87  
gaze holding and velocity-to-position neural integrator and, 96  
gaze-shifting, 87–88  
nystagmus and, fast phases of, 99–100, 100f  
off-vertical axis stimulation and, 93–94, 94f  
optokinetic reflex and, 91, 91f  
otolith-ocular reflexes and, 91–93, 92f  
rapid, saccade-like, 233  
electrically induced, in mice, 235–238, 237f  
measurement of, 233–234, 234f  
spontaneous, in mice, 234f, 234–235, 236f  
reasons for studying, 87  
recordings of, applications of, 100–101  
visual-vestibulo-ocular reflex and, 89f, 89–91, 90f
- Eyeless*. See *Pax6*
- F**
- Fear conditioning, cued and contextual, 27
- Fetal loss, in *Ndph* knockout mice, 534–535
- Fgfr signaling, lens development and, 276–277
- Field mice, 5
- Filensin, cataracts and, 498–499
- Fixation mechanism, 88
- Fluorescence resonance energy transfer (FRET), 597
- Fluorescent reporters  
under control of *Thy-1* promoter, 598  
subcellular spatial resolution using, 597
- Fontana's spaces, 130
- Force-choice apparatus, two-alternative, for visual acuity measurement, 18, 20
- Forced choice discrimination task, for measuring visual perception, 109
- Formalin test, 25
- Forward genetics approach, 66–67, 67f
- Fox*, cataracts and, 494
- Foxd1*, chiasm patterning and, 396
- FOXE3, in cornea and lens development, 701
- Foxe3*, lens development and, 277
- Foxg1*, chiasm patterning and, 396
- Foxn4*, *Math5* repression in retinal progenitor cells and, 326
- Frs2α*, lens development and, 277
- Fungal infections, mouse models of, 508
- FVB/N strain, 15  
FVB/NJ  
anxiety-related behavior tasks and, 29  
auditory evoked brainstem response in, 22  
avoidance learning in, 28  
hearing and visual abilities in, 15t  
pain sensitivity in, 25  
pattern discrimination in, 18  
visual acuity of, 20  
mutation and effect in, 62t
- FVBS/Ant strain, 15
- G**
- GABAC* null mice, refractive errors in, 83
- GABA<sub>C</sub>R*, inhibition mediated by  
alteration of visually and electrically evoked responses of ON-center retinal ganglion cells by, 183–184, 184f  
control of output of bipolar cell synaptic output by, 182–183
- GABAergic* neurons, of superior colliculus, 239
- GAD67 (Gad)*-GFP knock-in mice, *GABAergic* neurons in, 239
- Galactose feeding, diabetes and, 550
- $\alpha(1,3)$ -Galactosyltransferase, cataracts and, 499
- Ganglion cell(s), gap junctions of, 169, 170f, 171  
functional role of, 171
- Ganglion cell layer (GCL), 635, 636f
- GAP-43*, retinal ganglion cell axon guidance through visual pathway and, 392f, 393
- Gap junctions, 165–171  
of amacrine cells, 167  
of bipolar cells, 167  
transgenic mice to study, 596–597  
ganglion cell coupling and, 169, 170f, 171  
functional role of, 171  
of horizontal cells, 166f, 166–167  
of photoreceptors, 165–166, 166f  
in proximal rod pathways, 167–169, 168f  
retinal waves and, 346–347
- Gaze holding, oculomotor neural integrator and, 96
- Gaze-shifting movements, 87, 88
- GCI-/-* mice, as model for Leber congenital amaurosis, 611
- Gdf3/Myostatin*, control of retinal progenitor cell proliferation by, 328
- Geminin, eye field transcription factor regulation and, 302
- Gene(s). See also *specific genes*  
controlling vision, finding, 62–63, 64f, 65f  
epistatic interaction between, 651–653, 652t
- Gene deletion, to define role of cholinergic signaling by starburst amacrine cells, 598
- Gene expression, 685–694, 686f  
analysis of  
correlation of retinal pigment epithelium gene expression and retinal vascularization and, 692–693  
isolation of retinal pigment epithelium and, 688, 689f, 690f, 690–691  
isolation of retinal vasculature and subsequent gene expression studies and, 688, 689f, 691–692  
study methods for, 686–687  
transgenics in, 692
- in cornea and lens, 697–706  
cornea and lens development and, 697, 698f  
large scale analyses of, 698–699  
regulation of specific genes and, 703–705  
transcription factors and, 699f, 699–703, plate 66
- degeneration networks by expression profiling of photoreceptors from *rd* mice and, 679–680
- drug-controlled  
*Cre-lox* recombinase system for study of, 600f, 600–601  
reversible, 601
- expression profile of mRNA from whole mouse retinas at different postnatal developmental stages and, plate 65
- inducible, in differentiated Müller glia, plate 61
- mapping of, for ocular dominance plasticity assessment, 442–443
- in mouse eye, 662
- in retinal pigment epithelium  
correlation of retinal pigment epithelium gene expression and retinal vascularization and, 692–693  
isolation of retinal pigment epithelium and, 688, 689f, 690f, 690–691
- in retinal vasculature  
correlation of retinal pigment epithelium gene expression and retinal vascularization and, 692–693  
isolation of retinal vasculature and subsequent gene expression studies and, 688, 689f, 691–692  
spatial regulation of, using cell type-specific promoters, plate 58
- Gene expression profiling, 654–655

- Gene targeting methods, 594–595, 595f
- Gene therapy
  - antiangiogenic, 607
  - neurotrophic factor, 613
  - for retinal degeneration, 675
  - vectors for, 605
    - adenoassociated virus. *See* Adenoassociated virus (AAV) gene therapy
- Gene transfer methods, 593–594, 594f. *See also* Electroporation
- Genetic modifiers
  - as cause of phenotypic variation, 651–653, 652t
    - retinal degeneration and, 652–653
  - cloning of, strategies for, 653–655
    - chromosomal localization of modified traits and, 653–654
    - gene expression profiling and, 654–655
    - haplotype analysis and, 654
    - microarray analysis and, 654–655
    - modifier screens using mutagenesis and, 655
    - segregating crosses with multiple strains and, 654
- Genetic networks in mouse eye, 667f, 667–668
  - microarray methods and, 669
- Genetic tagging technique, to ablate starburst amacrine cells, 598
- Genomics, glaucoma therapy and, 488
- GFP, expression in rods, plate 63
- Ggta1*, cataracts and, 499
- Gja3*, cataracts and, 495–496
- Gja8*
  - cataracts and, 496, 496f, 588
  - mutations of, plate 37
- Glaucoma
  - future prospects for new therapies for, 487–488
    - genomics and proteomics and, 488
    - neuroprotection as, 487–488, 488f
  - genetic component in, 479
  - human clinical research on, pattern electroretinography in, 124
  - mouse models of, 479–489
    - accuracy of intraocular pressure measurements in, 480
    - advantages of, 479
    - of developmental glaucoma, 483
    - experimentally induced glaucoma and, 481
    - pattern electroretinogram application in, 122–124, 123f
    - of pigmentary glaucoma, 483–485, 484f
    - of primary congenital glaucoma, 483
    - of primary open-angle glaucoma, 481–482
    - similarity between mouse and human structures relevant to, 479–480
  - mutagenesis and new models of, 488–489
  - neurodegeneration and, 485, 485f
  - optic nerve excavation in, prevention by radiation treatment, plate 35
  - overview of, 479
    - primary open-angle
      - models of, 489
      - mouse model of, 481–482
    - retinal ganglion cell death in
      - regional patterns of, 485–486, plate 33
      - soma death and axon degeneration and, 486–487, 487f
    - treatment of, 644
      - future prospects for new therapies for, 487–488
- Glaucomatous optic neuropathy, retinal ganglion cell axon regeneration in, 409
- Gli family, control of retinal progenitor cell proliferation by, 329
- Glial cell(s), in optic nerve, 201–202
- Glial cell line-derived neurotrophic factor (GDNF), 613
  - retinal ganglion cell axon growth and, 401
- Glial fibrillary acidic protein-green fluorescent protein (GFAP-GFP) transgenic mice, 287
- Glucagon amacrine cells, in mouse versus chicken eye, 82–83
- GluR6, signaling through, 596
- Glycine receptor  $\alpha 2$ , photoreceptor development and, 305
- Gnao1<sup>tm1Lbi</sup>* mice, control of depolarizing bipolar mGluR6 signaling cascade in, 178–179, 179f
- Gpmmb<sup>R130X</sup>*, pigmentary glaucoma and, 483
- Grm6<sup>sub4</sup>* mice
  - control of depolarizing bipolar mGluR6 signaling cascade in, 178–179, 179f
  - retinal ganglion cell responses in, 181
- Grm6<sup>Tm1Nak</sup>* mice
  - control of depolarizing bipolar mGluR6 signaling cascade in, 178–179, 179f
  - retinal ganglion cell responses in, 181
- Growth, of retinal ganglion cell axons. *See* Retinal ganglion cells (RGCs), axon growth and regeneration of
- Growth factors. *See also specific growth factors*
  - lens and, 273
  - retinal vascularization and, 286–287
- Growth of mouse eye, 74
- Guidance molecules, retinal vascularization and, 288
- ## H
- Habituation-discrimination test, 22–23
- Habituation-dishabituation test, 22–23
- Hamilton Eye Institute Mouse Database (HEIMED), 664
  - BXD Genetic Reference Panel of Mice and, 664–665, 666t, 667
  - genetic networks in eye and, 667, 667f
  - quantitative trait locus mapping in, 668–669, 670
- Hargreaves test, 24, 25
- Hartmann-Shack aberrometry
  - optical aberration measurement using, 79f, 79–80
  - spherical aberration found on, 75–76
- Head tilt mice, 101
- Hearing, in mice, 15t
- Hearing ability, measurement of, 20, 22
- Hearing loss, in *Ndph* knockout mice, 533–534
- Heat shock transcription factors
  - cataracts and, 496–497
  - in cornea and lens development, 702
- Hematopoietic stem cells (HSCs), retinal vascularization and, 289
- Herpes simplex virus (HSV) infections, 505
- Herpes stromal keratitis (HSK), 505–506
- Hes1
  - eye field formation and, 301
  - retinal development and, 324
- Hes5, eye field formation and, 301
- Hind limb denervation, as model of
  - anesthesia dolorosa, 25
- Hmg1, in cornea and lens development, 701
- Horizontal cells
  - development of, Rb and, 318
  - gap junctions of, 166f, 166–167
  - mosaic architecture of, 148–150, 149f, 150f
- Hot-plate test, 24–25
- House mice, 5
- Hsf4*, cataracts and, 496–497
- Hspg2*, cataracts and, 499–500
- Human genome, 660
- Human leukocyte antigen (HLA) transgenic mice, experimental autoimmune uveitis in, 516
- Hyperoxia, depletion-induced, lack of oxygen supply to outer retina and, 565–566
- Hyperpolarizing bipolar cells (HBCs), 136
  - synaptic transmission in outer retina and, 176f, 176–179, 177t
- Hypopigmented mice, 61
- ## I
- I- $\kappa$ B- $\zeta$ , in cornea and lens development, 702
- I/LnJ mice, auditory evoked brainstem response in, 22
- Immunoprecipitation (IP), visual cycle protein interactions and, 729
- Impact-rebound (I/R) tonometry, 480
- Inbred strains
  - genetic variability in, 668
  - power of, 668
  - used for research, 13
    - on lens, 271–272
- Inducible nitric acid synthase (iNOS), diabetic retinopathy and, 553
- Inducible RNAi, in retina, plate 62
- Infantile neuronal ceroid lipofuscinosis (INCL), gene replacement therapy for, 612
- Infectious eye diseases, 505–509
  - bacterial, 506–508
  - fungal, 508
  - herpetic, 505–506
  - parasitic, 508–509
  - retinal, mouse models of, 509

Inferometry, low-coherence, 77–79, 78f  
 Infrared photoretinography, 74–76, 76f, 77  
 Inhibitory postsynaptic potentials (IPSPs), in lateral geniculate nucleus, 420, 421f  
 Inner plexiform layer (IPL)  
   dendrites in, 194  
   lateral inhibition in, 175  
 Insulin-like growth factor (IGF)  
   cell death and, 336  
   retinal ganglion cell axon growth and, 401  
 Insulin-like growth factor-1 (IGF-1)  
   eye field formation and, 301  
   overexpression of, 554  
   visual cortical plasticity and, 456  
 Interferometer, Michelson, 79  
 Interferon- $\tau$  (IFN- $\tau$ )  
   experimental autoimmune uveitis and, 520  
   *Pseudomonas aeruginosa* infections and, 507  
 Intergeniculate leaflet (IGL), retinal projections to, 40, 41  
 Interlaminar connections, in superior colliculus, 239, 240f  
 Interleukin-1 $\beta$  (IL-1 $\beta$ ), diabetic retinopathy and, 553  
 Interleukin-8 (IL-8)  
   proliferative retinopathy and, 292, 293  
   *Pseudomonas aeruginosa* infections and, 507  
 Interphotoreceptor retinoid-binding protein (IRBP)  
   experimental autoimmune uveitis induced by, 515  
   in visual cycle, 726  
 Intracellular adhesion molecule-1 (ICAM-1), diabetic retinopathy and, 553  
 Intraocular pressure (IOP)  
   aqueous humor outflow and, 131  
   measurement of, accuracy of, 480  
 Ischemic optic neuropathy, retinal ganglion cell axon regeneration in, 409  
 Islet2  
   retinal ganglion cell axon divergence at chiasm and, 395  
   as retinal ganglion cell marker, 193  
 Isoelectric focusing (IEF), in proteomics, 713–714  
 Isomerohydrolase, in visual cycle, 723–724

## J

Jackson Laboratory, 13, 581–582  
 Junctional adhesion molecule-B (JAM-B), as retinal ganglion cell marker, 193  
 Juxtacanalicular connective tissue (JCT), 131, 131f

## K

Keratins, expression in cornea, 705  
 Keratitis, stromal, herpes, 505–506  
 Keratocan, expression in cornea, 705  
 Keratomycosis, 508  
 Kessler, Paul Leonhard, 270  
 Kinases, cell death and, 338  
 KKAY mouse  
   diabetes in, 550

diabetes-induced retinal neurodegeneration in, 551  
 Knockout mouse models, 65, 635–645. *See also specific models*  
   anterior chamber cell types and, 644–645  
   developers of, 35  
   for lens research, 273–274  
   P7, plate 42  
   refractive errors in, 83  
   retinal cell types and, 635, 636f, 637  
   retinal pigment epithelium and, 637–639, 639f  
   vascular cell types and, 639–643, 641f, 643f

## L

Lac repressor-lac operator system, for study of retinal ganglion cells, 599  
 Lamina cribrosa (LC), in glaucoma, 485–486  
 Lamina cribrosa region, of optic nerve, 201, 202f  
 Lang, Richard, 275  
 Lateral geniculate nucleus (LGN)  
   cellular composition of, 419  
   differentiation of neurons of, 419  
   dorsal. *See* Dorsolateral geniculate nucleus (dLGN)  
   excitatory responses in, 420, 422, 424  
   eye-specific segregation in, development of, 415–416, 416f, 417f, 418  
   inhibitory responses in, 422  
   retinal ganglion cell projections to, 192  
   synaptic connectivity patterns in, 422, 423f, 424  
   synaptic remodeling in, 429–430, 430f, 430–431, 431f  
   activity and, 431–432  
   comparison with remodeling in other regions of visual system, 433–434  
   cortical critical period in, 433  
   genes involved in, 434–435  
   plasticity in lateral geniculate nucleus and, 432–433  
   superior colliculus and, 433–434  
   vision-sensitive phase of, 433  
 Lateral terminal nuclei (LTN), retinal projections to, 41  
 Lateromedial area, extrastriate, intracortical connections of, plate 9, plate 10  
 Lathrop, Abbie, 13  
 Learning tasks, 25–29  
   visually dependent, 25–28  
   visually independent, 28–29  
 Leber congenital amaurosis (LCA), gene replacement therapy for, 611–612  
 Lecithin:retinol acyltransferase (LRAT), in visual cycle, 723  
 Le-Cre strain, Cre expression in, plate 12  
 Lens, 267–279  
   cell proliferation in, 270  
   connexins in, cataracts and, 495–496, 496f  
   crystallins in, 703–704, 704f, 711–713, 716, 716f  
   posttranslational modification of, 716

posttranslational modifications and, 715  
 development of, 267, 268f, 697, 698f  
   transcription factors involved in, 699f, 699–703, plate 36  
 epithelial cells of, 267  
 fiber cells of, 267  
 function of, 267–268  
 gene expression in. *See* Gene expression, in cornea and lens  
 lens transplantation experiments and, 270  
 membranes of, mutations affecting, 495–496  
 morphological descriptors of, 270  
 mutations affecting structural proteins of, cataracts and, 496–499  
 proteomics of, 711–718, 716f  
   crystallins and, 711–713, 716  
   posttranslational modifications and, 715  
 refractive power of, 73  
 research on development of  
   conditional gene alterations using Cre recombinase and, 274–275, 275f  
   customizing mouse genome for, 273–274  
   differences among mouse strains and, 271–272  
   historical background of, 268–269  
   lens complementation system for, 274  
   lens fiber differentiation and, 278  
   molecular biology and, 272  
   mouse and human lenses compared and, 270–271  
   mouse lens induction and, 275–278, 276f  
   murine models for, 269–270  
   nonmurine model systems for, 268–269  
   transgenic mice for, 272–273  
   structure of, 267  
 Lens complementation system, 274  
 Leukemia inhibitory factor (LIF), retinal vascularization and, 287  
 Leukocytes  
   adherence in retinal microvasculature of diabetic mouse, plate 47  
   mouse model of oxygen-induced retinopathy and, 293–294  
*Lhx2*, as eye field transcription factor, 300  
 Lid suture, deprivation myopia from, 82  
 Liegeois, Nanette, 274  
 Light  
   acceleration of photoreceptor degeneration by, lack of oxygen supply to outer retina and, 566  
   continuous, refractive development and, 82  
   raising of oxygen levels in outer retina by, 565  
   responses to exposure to, *Rpe65* alleles and, 650–651  
   retinal degeneration induced by, 16, 573  
   mouse strains with, 16  
 Light-dark transition test, 29  
*Lim2*, cataracts and, 495  
 Lineage tracing, Cre-lox recombinase system for study of, 601

- Linear control systems analysis, 88n  
 Linear model of evolution, 6–7, 7f  
 Linear vestibulo-ocular reflex (IVOR), 88  
*Lip12*, cataracts and, 588  
 Lipofuscin, in retinal pigment epithelium, 539–544, 540f, 638  
   autofluorescence of, plate 44  
   inhibiting formation of fluorophores and, targeting visual cycle for, 543f, 543–544  
   Leu450Met variant in murine Rpe65 associated with, 542–543, 543f  
   Rpe65<sup>-/-</sup> mice and, 539–540, 540f  
   Stargardt macular degeneration and *Abca4/Abcr* null mutant mice and, 540–542, 541f  
 Liquid chromatography, in proteomics, 714  
*Listeria monocytogenes* infections, 508  
 Little, Clarence Cook, 13, 269  
 Long-term depression (LTD)  
   AMPA receptors and, 470  
   aVOR gain and, 100  
   ocular dominance shift and, 468  
 Long-term potentiation (LTP)  
   mechanism for, 471  
   ocular dominance shift and, 468  
   retinoic acid and, 366  
*Lop10*, cataracts and, 588  
 Low-coherence interferometry, 77–79, 78f  
*Lrat*<sup>-/-</sup> mice, 723  
 Lucentis (ranibizumab), for age-related macular degeneration, 607  
 Lurcher mice, 101  
 Lysosomal storage disease, gene replacement therapy for, 612
- M
- Mab21/2*, lens development and, 277  
 MacDowell, E. Carlton, 13  
 macrophage inhibitory protein-2 (MIP-2), herpes simplex virus infection and, 506  
 Macrophages, mouse model of oxygen-induced retinopathy and, 294  
 Macugen (pegaptanib), for age-related macular degeneration, 607  
 Macular degeneration  
   age-related, gene therapy for, 607  
   Stargardt, in *Abca4/Abcr* null mutant mice, 540–542, 541f  
*Maf*, cataracts and, 494  
 Maf transcription factors, in cornea and lens development, 702  
 Magnetic search coil oculoigraphy, 89  
 Major histocompatibility complex I (MHC I)  
   antigen, lateral geniculate nucleus synaptic remodeling and, 434–435  
 MA/MyJ strain, auditory evoked brainstem response in, 22  
 Mann, Ida, 269  
 Mass spectrometry  
   in proteomics, 714  
   visual cycle protein interactions and, 729
- Maternal care, neuronal and behavioral development and, 451, 455–456, 458  
*Math5*  
   circadian photoentrainment and, 210, 211–212  
   regulation of expression of, 325–327  
     of duration of expression, 325–326, 326f  
     *math5* activation in retinal progenitor cells and, 325  
   repressing expression in other retinal progenitor cells and, 326–327  
   retinal ganglion cell development and, 324–325  
     activation of retinal ganglion cell fate and, 325  
     cell cycle progression and, 324  
     retinal ganglion cell competence and, 324  
     suppression of non-retinal ganglion cell fates and, 324–325  
   retinal ganglion cell differentiation downstream of, regulation of, 327–329  
   control of retinal progenitor cell proliferation by retinal ganglion cell-secreted signaling molecules and, 328–329  
   genes regulated by Pou4f2 and, 327–328  
   regulation of retinal ganglion cell axon outgrowth and pathfinding and, 328  
   transition for retinal ganglion cell competence to retinal ganglion cell commitment and, 327
- Math5*  
   expression in retinogenesis, plate 16  
   retinal ganglion cell development and, 194  
 Matrix metalloproteinase-9 (MMP-9), corneal neovascularization and, 506  
 Mechanical sensitivity, von Frey filament test of, 24  
 Medial terminal nucleus (MTN), retinal projections to, 41  
 Melanoma antigen, anti-tumor response to, uveitis associated with, 516  
 Melanopsin, 213–214  
   phototransduction mechanism and, 213–214  
 Melanosomes, DBA/2J pigment dispersion and, plate 32  
 Membrane currents, in dorsolateral geniculate nucleus, 220f, 220–221  
 Memory tasks  
   visually dependent, 25–28  
   visually independent, 28–29  
 Mesencephalon, visual cortex connections with, 46  
 Michelson interferometer, 79  
 Microarray analysis, 654–655, 663–667  
   BXD Genetic Reference Panel of Mice and, 664–665, 666t, 667  
   defining genetic networks in, 669  
   expression profiling using, 675–676  
   gene expression and, 686–687
- Hamilton Eye Institute Mouse Database and, 664  
 Microarray-based technologies, glaucoma therapy and, 488  
 Microglia, mouse model of oxygen-induced retinopathy and, 293–294  
 Microphthalmia, in C57BL mice, 271  
*Mip*, cataracts and, 495  
 MLR10 mice, 274–275  
   Cre expression in, plate 12  
 MLR39 mice, 275  
   Cre expression in, plate 12  
 MOLF/Eij strain  
   anxiety-related behavior tasks and, 29  
   hearing and visual abilities in, 15t  
   pattern discrimination in, 18  
   visual acuity of, 20  
 Monocular deprivation (MD)  
   in juvenile mice, effects of, 468, 469f, 470f  
   ocular dominance shift and, 470–471  
   ocular dominance studies and. *See* Ocular dominance (OD) plasticity  
 M-opsin, cone, expression of, 136, 138–139  
 Morris water maze, 25–26, 26f  
   for measuring visual perception, 109–110  
 Mosaic architecture, of retina, 147–153  
   cholinergic amacrine cells and, 150–151, 151f  
   development of, 147–148, 148f  
   dopaminergic amacrine cells and, 151–153  
   horizontal cells and, 148–150, 149f, 150f  
 Mouse genome, 660–662  
   sequence differences among mice and, 660–662, 661f, 662t  
 Mouse hepatitis virus (MHV) infections, 509  
 Mouse models. *See also specific models*  
   advantages of, 363  
   historical background of, 61–62, 62t  
   mutant. *See also specific models*  
     eye movements and, 100–101  
     of synaptic transmission in outer retina, 176f, 176–179, 177t  
   *Mox-Cre;Rb<sup>Lox/Lox</sup>* mice, rod development in, 314  
 Mucopolysaccharidosis type VII (MPS VII), gene replacement therapy for, 612  
 Müller glia, differentiated, inducible expression in, plate 61  
 Multielectrode arrays (MEAs), for retinal wave measurement, 343  
 Murine coronavirus infections, 509  
 Murine cytomegalovirus infections (MCMV), 509  
*Mus*, 3–8  
   phylogenetic relationships in genus, 8  
   subgenera of, 3–6, 4f  
*Mus booduga*, 5, 8  
*Mus caroli*, 8  
*Mus cervicolor*, 5, 8  
*Mus Coelomys*, 3–5, 8  
*Mus cookii*, 8  
*Mus crociduroides*, 5  
*Mus cypricus*, 6  
*Mus famulus*, 5, 8  
*Mus fernandoni*, 5

- Mus fragilicauda*, 5, 8  
*Mus lepidoides*, 5–6, 8  
*Mus macedonicus*, 6, 8  
*Mus mayori*, 5  
*Mus Mus*, 3–4, 8  
*Mus mus castaneus*, 6, 7, 8  
*Mus mus domesticus*, 6–7, 8  
*Mus mus gentilulus*, 6, 7, 8  
*Mus mus musticus*, 6, 7, 8  
*Mus musculus*, 3, 5, 6, 8  
    evolutionary history of, 6–8, 7f  
*Mus Nannomys*, 3, 5, 8  
*Mus nitidulus*, 5, 8  
*Mus pahari*, 5  
*Mus phillipsi*, 5  
*Mus plathythrix*, 5  
*Mus Pyromys*, 3–4, 5, 8  
*Mus Sensu stricto*, 5  
*Mus shortridgei*, 5  
*Mus spicilegus*, 6, 8  
*Mus spretus*, 6, 8  
*Mus terricolor*, 8  
*Mus vulcani*, 5  
Mutagenesis, modifier screens using, 655  
Mutant mouse models, 14. *See also specific models*  
    eye movements and, 100–101  
    of synaptic transmission in outer retina, 176f, 176–179, 177t  
    postsynaptic mouse mutants and, 177t, 178–179, 179f  
    presynaptic mouse mutants and, 177t, 177–178  
Muthukkaruppan, V., 269–270  
Myelinated portion, of optic nerve, 201, 202f  
Myelinogenesis, of optic nerve, 201–202  
*MYO7A*, age-related eye diseases and, 584  
Myocilin (*MYOC*), in primary open-angle glaucoma, 481–482  
Myopia, deprivation  
    induced by frosted diffusers, 82  
    from lid suture, 82
- N
- nAChR subunits, retinal waves and, 345–346  
*Nakano cataract*, 501  
Nance-Horan syndrome (NHS), 499  
*Nbn* gene, senile cataracts and, 500  
*NDP*, 528  
    evolutionary conservation and expression pattern of, 528, 529f  
*Nlph*, 529–530  
*Ndst1*, lens development and, 277  
Negative masking, circadian  
    photoentrainment and, 210  
Neo-antigen-driven experimental autoimmune uveitis, 515–516  
Neovascularization  
    choroidal, gene therapy for, 610  
    corneal, matrix metalloproteinase-9 and, 506  
    retinal  
        gene therapy for, 607, 609–610  
        limitation by laser burns, 565  
        protection against, by degradation of photoreceptors, 565  
Netrin-1  
    regulation of retinal ganglion cell axon exit from eye by, 383f, 384  
    retinal ganglion cell axon guidance through visual pathway and, 392, 392f  
NEUBank, 663  
Neurodegeneration, glaucoma and, 485, 485f  
Neurofilament H, antibodies against, as retinal ganglion cell marker, 193  
Neuroglobin, retinal oxygen consumption and, 562  
Neuronal plasticity, RALDH3 colocalization with markers for, 368, 369f  
Neuronal tissue, in optic nerve, 201  
Neuron-specific enolase (NSE), cell death and, 337  
Neuropathic pain, measurement, 25  
Neuroprotection, for glaucoma treatment, 487–488, 488f  
Neurotrophic factor gene therapy, 613  
Neurotrophin(s), cell death and, 336  
Neurotrophin-3  
    postnatal cortical maturation patterns defined by, 369–370, 370f  
    RALDH3 relationship with, 368–369, 369f  
Neutrophils, *Pseudomonas aeruginosa* infections and, 507  
Nhs1 protein, cataracts and, 499  
Night blindness, stationary, congenital, 650  
NMDA, excitatory lateral geniculate nucleus responses and, 420  
NMDA receptors (NMDARs), 223–225  
    ocular dominance shift and, 469  
    in reticulogeniculate synapses, 431, 439  
NMDA-type glutamate receptor antagonist, stratum griseum intermediale burst generation and, 240  
*nob* knockout mice, refractive errors in, 83  
NOD strain, diabetes in, 550  
NOD/LtJ strain, auditory evoked brainstem response in, 22  
Noggin, eye field formation and, 301  
Nonpigmented ciliary epithelium (NPE), 129  
*Nop*, cataracts and, 497  
NOR/LtJ strain, auditory evoked brainstem response in, 22  
Norrie, Gordon, 527  
Norrie, function of, 528–529  
Norrie disease, 527–535  
    clinical background of, 527  
    extraocular features of, 527  
    knockout mouse model for, 529–530  
        abnormal retinal vascular development in, 530–531, 531f, 532f  
        ectopic norrin expression in lens and, 534  
        fetal loss in homozygous females and, 534–535  
        hearing loss and abnormal cochlear vasculature in, 533–534  
        hyaloid vessel regression versus angiogenesis of retinal blood vessels in, 532, 533f  
        phases of, 532–533  
        retinal physiology of, 530  
        sprouting angiogenesis failure in, 531–532  
    molecular basis of, 527–528  
    NDP gene conservation and expression pattern and, 528, 529f  
    norrin and, 528–529  
    transgenic mouse line with norrin overexpression in lens and, 534  
Norrin, 528  
    ectopic expression in lens, rescue of knockout phenotype by, 534  
    overexpression in lens, transgenic mouse line with, 534  
Norrin knockout mice, hematoxylin-eosin-stained sections of whole eyes from, plate 43  
Notch pathway  
    eye field formation and, 301  
    retinogenesis regulation and, 303–304  
*Npp*, 501  
Nr-CAM, retinal ganglion cell axon divergence at chiasm and, 394f, 395  
*Nr2e3*, rod development and, 316  
*Nr2e3*, photoreceptor development and, 304–305  
NRL, gene profiling of purified photoreceptors and, 676, 677f  
Nrl, photoreceptor development and, 304–305  
*Nrl*, rod development and, 316  
*Nrl<sup>-/-</sup>* knockout mice  
    as model for central field loss, 613  
    photoreceptors of  
        caveats for investigations of, 142  
        cones as, 139, 141–144  
        cone-specific genes and their molecular function and, 143–144  
        differentiation of, 143  
        mouse cone protein biochemistry and, 144  
        prospects for studies using, 143–144  
*Nuclear posterior polar opacity*, 501  
Nucleus of the optic tract (NOT), retinal projections to, 41  
Null mutation. *See* Knockout mouse models  
Nystagmus  
    fast phases of, 99–100, 100f  
    off-vertical axis rotation engendering, 94  
    optokinetic, velocity storage integrator and, 95f, 95–96  
    optokinetic after-nystagmus and, 94  
    postrotatory, 94  
*Nyx<sup>nob</sup>* mice  
    control of depolarizing bipolar mGluR6 signaling cascade in, 178–179, 179f  
    retinal ganglion cell responses in, 181  
NZB/BINJ strain, taste ability in, 23  
NZW strain, mutation and effect in, 62t  
NZW/LaJ strain, photoreceptor response damage by light and, 575, 577

## O

- ob/ob mice, diabetes in, 550
- Ocular dominance (OD), mapping of, plate 26
- Ocular dominance (OD) plasticity, 439–446.  
*See also* Visual cortical plasticity, experience-dependent
- adult, 443, 444f, plate 27
- enhancement by prior experience, 445f, 445–446, 446f
- mechanisms of, 443–445
- behavioral correlates of, 447
- chondroitin sulfate proteoglycans and, 454–455
- extended duration visually evoked potentials for assessment of, plate 31
- juvenile, mechanisms of, 443–445
- methods for assessing, 439–443
- calcium imaging with two-photon microscopy as, 441–442, 442f
- mapping of gene expression as, 442–443
- optical imaging as, 440f, 440–441, 441f
- single-unit recordings as, 439
- visually evoked potentials as, 439–440
- ocular dominance column plasticity and, 465–466
- Ocular hypertension, treatment of, 644
- Oculography, applications of, 101
- Oculomotor control, importance of, 87
- Oculomotor neural integrator, 96
- Odor discrimination ability, measurement of, 22–23
- Odor preference, conditioned, 28
- Off-vertical axis rotation (AVOR), 93–94, 94f
- Olfactory ability, measurement of, 22–23
- Olfactory tubing maze, 28
- Oligodendrocytes, in optic nerve, 202
- Olivary pretectal nuclei (OPT), retinal projections to, 41
- ON and OFF pathways in mouse retina, 353–360
- cellular and synaptic structure of, 353–354, 354f
- segregation of
- mechanisms of, 358–360, 359f, 360f
- retinal synaptic circuitry development and, 354–357, 355f, 356f
- synaptic activity and, 357–358
- Onchocerca volvulus* infections, 508
- 129/J. *See* 129P3/J strain
- 129P3/J strain
- auditory evoked brainstem response in, 22
- mutation and effect in, 62t
- 129P3/PJ, mutation and effect in, 62t
- pain sensitivity in, 25
- tactile sensitivity in, 24
- 129/ReJ strain, auditory evoked brainstem response in, 22
- 129S1/SvImJ strain
- hearing and visual abilities in, 15t
- 129/S1, olfactory ability in, 22, 23
- pattern discrimination in, 18
- photoreceptor response damage by light and, 575, 577
- visual acuity of, 20
- 129S2/Sv strain, anxiety-related behavior tasks and, 29
- 129/SvEms strain, learning and memory in, 27
- 129/SvEvTac strain
- avoidance learning in, 28
- pattern discrimination in, 18
- 129SvJ. *See* 129X1/SvJ
- 129/SvPasCrl strain, conditioned odor preference in, 28
- 129Sv-ter/C57BL/6 mice, olfactory ability in, 22, 23
- 129X1/SvJ strain
- auditory evoked brainstem response in, 22
- pain sensitivity in, 25
- Open field test, 29
- Operant olfactometer, 22, 23
- Opn<sup>4</sup><sup>-/-</sup>* mice, circadian photoentrainment and, 210, 211
- Opsins
- of cones, expression of, 136, 138–139
- development of, 305
- signaling molecules responsible for expression of, 304–306
- Optic chiasm
- regulatory genes in retina and chiasm important for patterning, 396–397
- retinal ganglion cell axon divergence at, 393–396
- crossed projection and, 395–396
- uncrossed projection and, 393–395
- retinal ganglion cell axon guidance toward, 392f, 392–393
- Optic disc
- directed growth of retinal ganglion cell axons toward, 382–384, 383f
- targeting of retinal ganglion cell axons to, 383f, 383–384
- Optic disc astrocyte precursor cells (ODAPs), 390, 390f
- Optic fiber layer (OFL)
- control of initial retinal ganglion cell axon outgrowth polarity in, 381–382, 382f
- retinal ganglion cell axon restriction to, 379–381, 380f
- Optic nerve, 201–204
- astrocytes and astrocyte progenitors in, 390, 390f
- connective tissue in, 203, 203f
- development of, 201–202
- glaucomatous excavation of, prevention by radiation treatment, plate 35
- morphological features of, 201, 202f
- neuronal and glial tissue in, 202–203, 203f
- retinal ganglion cell axon projection through, 391–392, 392f
- vascular supply of, 203–204, 204f
- Optic nerve head, 201, 202f
- Optic neuritis, retinal ganglion cell axon regeneration in, 409
- Optic neuropathy
- glaucomatous, retinal ganglion cell axon regeneration in, 409
- ischemic, retinal ganglion cell axon regeneration in, 409
- traumatic, retinal ganglion cell axon regeneration in, 409, 409f
- Optic vesicle (OV), 267
- Optical imaging, for ocular dominance plasticity assessment, 440f, 440–441, 441f
- Optical interferometry tonometry (OIT), 480
- Optics, of mouse eye, 74
- Optineurin (*OPTN*), primary open-angle glaucoma and, 482
- Optokinetic after-nystagmus (OKAN), velocity storage integrator and, 95f, 95–96
- Optokinetic drum, 20
- Optokinetic nystagmus (OKN), velocity storage integrator and, 95f, 95–96
- Optokinetic reflex (OKR), 88, 91, 91f
- adaptation of, 98f, 98–99, 99f
- measurement of, 112–113, 114f
- Optomotor response, “whole body,” spatial vision and, 81–82
- Optomotor test apparatus, 17f
- Organelles, loss during lens differentiation, 278
- Orienting vestibulo-ocular reflex, 92
- Otolith-ocular reflexes, 91–92, 92f
- Outer nuclear layer (ONL), 635, 636f
- Outer plexiform layer (OPL), 637
- lateral inhibition in, 175
- Oxygen, 559–569
- delivery to retina, 559–561
- choroidal circulation and, 560–561
- retinal circulation and, 559–560
- inhaled
- blocking of vasogenesis by, 563
- killing of photoreceptors by, 562–563, 564f, plate 48
- lack of oxygen supply to outer retina and, 562–563, 563f
- lack of supply to outer retina, 562–568
- acceleration of photoreceptor degeneration by light and, 566
- degeneration of edge of normal retina and, 566–568, 567f
- depletion-induced hyperoxia and, 565–566
- inhaled oxygen and, 562–563, 563f
- reduction in photoreceptor metabolism and, 564–565
- retinal detachment and, 564
- oxygen stress during development and, 568, plate 49
- retinal consumption of, 561–562
- in adults, 561f, 561–562
- developmental onset of, 562
- neuroglobin and, 562
- retinal degeneration and, 568–569
- Oxygen-induced retinopathy (OIR), 285, 553–554
- epithelial cell death and, 293
- mouse model of, 289–294. *See also* Retinopathy, of prematurity (ROP)
- characterization of, 289–291, 291f, 292f
- cytokines and, 292–293
- endothelial cell apoptosis and, 293
- microglia and leukocytes and, 293–294

- Oxygen-induced retinopathy (continued)  
retinal flat-mount preparation from,  
plate 13  
VEGF-A and, 291–292
- P**
- P7 knockout mice, plate 42  
P7 wild type mice, plate 42  
P21 knockout mice, central retina from,  
plate 41  
P21 wild type mice, central retina from,  
plate 41  
p107  
retinal development and, 313  
rod development and, 316  
p130, retinal development and, 313  
Pac1r, circadian photoentrainment and,  
214  
Pain sensitivity, measurement of, 24–25  
Paramedian pontine reticular formation  
(PPRF), 238  
Parasitic infections, 508–509  
Pars plicata region, 129  
Pathogen-associated molecular patterns  
(PAMPs), 519  
Pattern electroretinogram (PERG), retinal  
ganglion cell activity measurement  
by, 119–124, 120f  
correlates of visual behaviors and,  
120–121, 121f  
in human clinical research, 124  
limitations of, 124  
methods for, 120  
in mouse models of glaucoma, 122–124,  
123f  
in study of central nervous system  
plasticity and degeneration, 121–122  
Pax6  
in cornea and lens development, 699–700  
eye field formation and, 301  
Notch1 retinal development and, 323–324  
*Pax6*  
cataracts and, 493  
as eye field transcription factor, 299  
Le-Cre mice and, 274  
lens development and, 275–277, 276f  
retinal ganglion cell development and,  
194  
retinal development and, 322–323  
*Pax6*Cre line, 598  
*Pax6-Cre;Rb<sup>Lux1/Lux</sup>* mice, rod development in,  
314, 315  
*Pde6b*, age-related eye diseases and, 584  
*Pde6b* gene, 14, 63  
*rd* mutation of, 61  
*rd1* mutation of, 26  
*Pdeb6b* mutations, 650  
*Pde6b<sup>rd1</sup>* mutation, 271  
Pearlman, Alan, 245  
*PEDF*, in gene therapy for retinal  
neovascularization, 607, 609  
Pentraxins, lateral geniculate nucleus  
synaptic remodeling and, 435  
*Per* genes, circadian photoentrainment and,  
214, 214f  
Pericyte(s), retinal vascularization and, 288,  
290–291  
Pericyte recruitment, 642  
Pericyte-derived angiopoietin-1, retinal  
vascularization and, 288  
Perlecan, cataracts and, 499–500  
Phakinin, cataracts and, 498  
Phenotypic variation  
alleles as cause of, 649–651  
genetic modifiers as cause of, 651–653,  
652t  
retinal degeneration and, 652–653  
Photokeratometry, 76–77, 78f  
Photoreceptors, 635, 636f, 637. *See also*  
Cone(s); Rod(s)  
candidates for light damage quantitative  
trait loci and, 577–579, 578t  
cell death of, pathways of, 678–679, 679f  
Cx36 expression by, plate 5  
degeneration of  
by light, 566  
*Pde6b* mutations leading to, 650  
*Rpe65* alleles and, 650–651  
*Rpgrip1* mutations leading to, 650  
degradation of, protection against retinal  
neovascularization by, 565  
depletion of, raising of oxygen levels in  
outer retina by, 565  
development of, 304–306  
biological network characteristics and  
relevance to photoreceptors and,  
676–677  
critical period in, 568  
hierarchy in regulatory networks  
underlying photoreceptor  
development and, 677–678, 678f  
NRL and gene profiling of purified  
photoreceptors and, 676, 677f  
expression profiling of, degeneration  
networks and, 679–680  
gap junctions of, 165–166, 166f  
killing of, by inhaled oxygen, 562–563,  
564f, plate 48  
by light damage of, 566  
light damage of, 573–579  
gene modifier having strong influence  
on, 573–575, 576f, 577, 577f  
of mouse compared to other mammalian  
species, 36  
at peripheral margin of retina, stress from  
early postnatal life and, plate 49  
phagocytosis of outer segments of, 638  
promoter transgenes and, 595  
reduction in metabolism of, lack of  
oxygen supply to outer retina and,  
564–565  
retinal pigment epithelium relationship  
with, 639  
targeted ablation to assess role of,  
595–596  
toxicity of depletion-induced hyperoxia to,  
565–566  
Photoretinoscopy, infrared, 74–76, 76f, 77  
Photosensitivity, circadian, 209  
Physical contact, plasticity and, 455f,  
455–456  
Pigment dispersion syndrome (PDS),  
483–485, 484f  
Pineal melatonin rhythm, circadian  
photoentrainment and, 210  
Pitx2, in cornea and lens development, 701  
*Pitx3*, cataracts and, 493–494, 494f  
*Pitx3*, in cornea and lens development, 701  
Placental growth factor (PGF), retinal  
vascularization and, 286–287  
Plasmids, delivery using electroporation. *See*  
Electroporation  
Plasminogen activator inhibitor-1 (PAI-1),  
diabetes and, 550–551  
Plasticity  
environmental enrichment and. *See* Visual  
cortical plasticity  
in lateral geniculate nucleus, mouse  
compared to other species and,  
432–433  
ocular dominance. *See* Ocular dominance  
(OD) plasticity  
reticulogeniculate synapses remodeling  
and, 431–432  
Platelet-derived growth factor-A (PDGF-A),  
retinal vascularization and, 287  
Platelet-derived growth factor-B (PDGF-B)  
diabetes and, 551  
retinal vascularization and, 288  
Postrotatory nystagmus (PRN), 94  
Posttranslational modifications, of proteins,  
715  
Potassium currents, in dorsolateral geniculate  
nucleus, 220–221  
POU homeodomain transcription factors, in  
cornea and lens development, 701  
POU4f1, retinal ganglion cell development  
and, 194  
Pou4f2  
expression in retinogenesis, plate 16  
genes regulated by, 327–328  
POU4f2, retinal ganglion cell development  
and, 194  
POU4f3, retinal ganglion cell development  
and, 194  
*PPT1*, 612  
P/Q mutants, 101  
Presumptive lens ectoderm (PLE), 267  
Primary congenital glaucoma (PCG), 483  
Primary open-angle glaucoma (POAG)  
models of, 489  
mouse model of, 481–482  
Prior experience, enhancement of ocular  
dominance plasticity by, 445f,  
445–446, 446f  
Promoter transgenes, and photoreceptors,  
595  
Prostaglandin analogues, for intraocular  
hypertension and glaucoma, 644  
Protein(s). *See also specific proteins*  
posttranslational modifications of, 715  
proteome-wide identification of species of,  
715  
Rb family of, retinal development and,  
311–319  
intrinsic genetic compensation and  
redundancy and, 312f, 312–313

Protein(s) (continued)  
 rod development and, 216f, 313–317, 315f  
 species-specific differences in Rb family compensation and, 313  
 synaptogenesis defects in Rb-deficient retinas and, 317–318, 318f

Protein-bound carbohydrates, cataracts and, 499–500

Proteomics  
 definition of, 711  
 glaucoma therapy and, 488  
 of lens, 711–718  
 of visual cycle, 727–729  
 of interacting components, 727–729

*Prox1*, lens fiber differentiation and, 278

*Prox1*, in cornea and lens development, 700–701

*Prph2<sup>Rd2/Rd2</sup>* mouse, gene replacement therapy for, for retinal degeneration in, 610–611

*prRd1<sup>-/-</sup>* mice, 723

*Pseudomonas aeruginosa* infections, 506–507, 508

*Ptf1a*, *Math5* repression in retinal progenitor cells and, 326–327

Purkinje cell degeneration mice, 101

## Q

Quantitative trait genes (QTGs), for light damage, 577–579, 578t

Quantitative trait locus (QTL) analysis, 63, 64f, 65f

Quantitative trait locus (QTL) mapping, 668–669, 670

## R

Radial arm maze, 26–27

Radial glia, midline, in retinal ganglion cell axon projection pathway, 390–391

Rafferty, Nancy, 270

RALDH3 band, medial, anatomical locations of, plate 20

Ramón y Cajal, S., 635

Rapid eye movements, saccade-like, 233  
 electrically induced, in mice, 235–238, 237f  
 measurement of, 233–234, 234f  
 spontaneous, in mice, 234f, 234–235, 236f

Rb family of proteins, retinal development and, 311–319  
 intrinsic genetic compensation and redundancy and, 312f, 312–313  
 rod development and, 216f, 313–317, 315f  
 species-specific differences in Rb family compensation and, 313  
 synaptogenesis defects in Rb-deficient retinas and, 317–318, 318f

RBP receptor, in visual cycle, 725

RDH5 gene, 725

*RDH12* mutations, 723

Receptive fields (RFs), of dorsolateral geniculate nucleus cells, 221–224, 223f

Refractive errors  
 induction of, by frosted diffusers or spectacle lenses, 82–83  
 in knockout mouse models, 83

Regeneration, of retinal ganglion cell axons.  
*See* Retinal ganglion cells (RGCs), axon growth and regeneration of

Regulatory networks  
 degeneration and, expression profiling of photoreceptors from *rd* mice and, 679–680  
 model for retinal ganglion cell development, plate 15  
 photoreceptors and, 676–677  
 underlying photoreceptor development, hierarchy in, 677–678, 678f

Reinforcement-based tasks, for measuring visual perception, 109–111, 111f–113f

Reticulogeniculate synapses. *See* Lateral geniculate nucleus (LGN), synaptic remodeling in

Retina  
 cell types in, 635, 636f, 637  
 developing, plate 14  
 electroporation and. *See* Electroporation gap junctions in. *See* Gap junctions inducible RNAi in, plate 62  
 layers of, plate 64  
 lineage tracing in, using cell type-specific promoters, plate 60  
 mature, plate 14  
 mosaic architecture of, 147–153  
 cholinergic amacrine cells and, 150–151, 151f  
 development of, 147–148, 148f  
 dopaminergic amacrine cells and, 151–153  
 horizontal cells and, 148–150, 149f, 150f  
 of mouse compared to other mammalian species, 35–39  
 multicolor labeling of, using cell type-specific promoters, plate 59  
 normal, degeneration of edge of, lack of oxygen supply to outer retina and, 566–568, 567f  
 outer, lack of oxygen supply to, 562–568  
 acceleration of photoreceptor degeneration by light and, 566  
 degeneration of edge of normal retina and, 566–568, 567f  
 depletion-induced hyperoxia and, 565–566  
 inhaled oxygen and, 562–563, 563f  
 reduction in photoreceptor metabolism and, 564–565  
 retinal detachment and, 564  
 outer, raising of oxygen levels in, by light, 565  
 oxygen consumption of, 561–562  
 in adults, 561f, 561–562  
 developmental onset of, 562  
 neuroglobin and, 562  
 oxygen delivery to, 559–561  
 retinal circulation and, 559–560

physiology of, in norrin knockout mice, 530  
 retinal ganglion cell axon exit from, 391  
 vascular development of, in norrin knockout mice, 530–531, 531f, 532f  
 whole mount, confocal image of, plate 4

Retinal antigen, experimental autoimmune uveitis induced by, 515, 516f, 517f

Retinal circulation, oxygen delivery to retina and, 559–560

Retinal degeneration, 675–680  
 age-related, in human and mouse eyes, 582, 584–588  
 expression profiling of photoreceptors from *rd* mice and, 679–680  
 expression profiling using microarrays and, 575–576  
 gene replacement therapy for, 610–611  
 gene therapy for, 675  
 genetic modification of, 652–653  
 light-induced, 16  
 mouse strains with, 16  
 mouse models of, 678–679, 679f  
 synaptic reorganization due to, 317–318

Retinal detachment  
 lack of oxygen supply to outer retina and, 564  
 retinopathy of, oxygen to relieve, 564

Retinal G protein-coupled receptor (RGR), in visual cycle, 724–725

Retinal ganglion cells (RGCs)  
 activation of, *Math5* and, 325  
 axon growth and regeneration of, 401–410  
 area of action of extracellular signals and, 402–403, 403f  
 control of neuronal responsiveness to trophic peptides and, 404f, 404–405  
 dendrite growth ability and, 406–407, 407f  
 developmental regulation of intrinsic growth and, 405–406, 406f  
 extracellular signals inducing growth and, 401–402, 402t  
 glaucoma and, 486–487, 487f  
 intrinsic and extrinsic control of regeneration and, 409–410  
 mechanism of axon induction by extracellular signals and, 403–404  
 molecular changes underlying developmental loss in rapid axon growth ability and, 407–408  
 need for specific extrinsic signals for growth and, 401, 402f  
 regeneration in mature visual system, 408–409  
 regulation of, 409–410  
 study of, 409, 409f  
 study of regeneration and, 409, 409f  
 axon outgrowth and pathfinding and, 379–386, 380f  
 control of initial polarity of outgrowth within optic fiber layer and, 381–382, 382f

- Retinal ganglion cells (continued)
- directed growth toward optic disc, 382–383, 383f
  - dorsal-ventral differences in
    - mechanisms regulating, 385–386
  - growth cones and guidance cues and, 379, plate 21
  - regulation of, 328
  - restriction of axons to optic fiber layer and, 379–381, 380f
  - targeting to optic disc and exit from eye, 383f, 383–385
  - axonal exit from retina and, 391
  - cell death of, 333, 334
    - in glaucoma, 479, 481, 485–487, 487f, plate 33, plate 34
    - matching sizes of interconnected neuronal populations and, 335, 335f
    - molecules involved in signaling, regulating, and executing, 337, 338
    - neurotrophic hypothesis of, 336
  - classes of, distinguishing, 189–190, 190f, 191f, 192
  - competence of, *Math5* and, 324
  - crush injury of, plate 23
  - dendrites of, growth ability of, axon
    - growth ability and, 406–407, 407f
  - development of, 321–330, 322f
    - developmental regulation of retinal ganglion cell subtypes and, 329
    - early regulatory events in, 322–324
    - gene regulatory network for, 321–322, 323f
    - Math5* and, 324–325
    - regulation of *Math5* expression and, 325–327
    - regulation of retinal ganglion cell differentiation downstream of *Math5* and, 327–329
    - in vitro generation of retinal ganglion cells from embryonic stem cells and, 329–330
  - developmental timing and, 261
  - differentiation of, downstream of *Math5*, regulation of, 327–329
  - direction-selective
    - calcium imaging of responses of, 598
    - genetic tagging to study responses of, 598
  - functional properties of, 192
    - development of, 194–197
  - generation and differentiation of, 193–194
  - generation from embryonic stem cells, in vitro, 329–330
  - genetic approaches for study of, 599
  - intrinsically photosensitive, 192, 211–212
    - morphology, ontogeny, and functional diversity of, 211–212, 212f
    - phototransduction mechanism and, 213–214
    - target brain regions innervated by, 212f, 212–213
  - melanopsin-expressing, circadian photoentrainment and, 210–211
  - molecular markers for, 192–193
  - morphological properties of, plate 6
    - development of, 194, 195f, 196f
  - of mouse compared to other mammalian species, 35, 37–38
  - ON and OFF pathway segregation and, 353–354, 355–360
    - mechanisms of, 358–360, 359f, 360f
    - retinal synaptic circuitry development and, 354–357, 355f, 356f
    - synaptic activity and, 357–358
    - synaptic circuitry development and, 355f, 355–357, 356f
  - ON-center, alteration of visually and electrically evoked responses of, by GABA<sub>C</sub>R-mediated feedback inhibition, 183–184, 184f
  - pattern electroretinogram measurement of function of, 119–124, 120f
    - correlates of visual behaviors and, 120–121, 121f
    - in human clinical research, 124
    - limitations of, 124
    - methods for, 120
    - in mouse models of glaucoma, 122–124, 123f
    - in study of central nervous system plasticity and degeneration, 121–122
  - phenotypes of, complex, altered outer retinal neurotransmission resulting in, 179
  - “pioneer axons” of, 389
  - projections of, 192, plate 6
    - albinism and, 397
    - axon divergence at chiasm and, 393–396
    - early development of, 389, 390f
    - glia in projection pathway and, 390–391
    - guidance cues and, 391f, 391–393, plate 21
    - late phase of development of, 390, 390f
    - middle phase of development of, 389–390, 390f
    - new approaches for study of, 397, 398f
    - regulatory genes in retina and chiasm important for chiasm patterning and, 396–397
    - techniques for studying, plate 22
  - retinal waves and. *See* Retinal waves
  - spontaneous burst activities of. *See* Retinal waves
  - subtypes of, developmental regulation of, 329
  - survival after lesion, 122, 123f
  - YFP expression, dendritic ramification patterns of, plate 19
  - Retinal infections, mouse models of, 509
  - Retinal neovascularization
    - Bcl-2 and, 293
    - gene therapy for, 607, 609–610
    - limitation by laser burns, 565
    - protection against, by degradation of photoreceptors, 565
  - Retinal network, of mouse compared to other mammalian species, 36f, 36–37
  - Retinal pigment epithelium (RPE), 637–639, 639f, plate 64
    - function of, 638
    - gene expression in
      - correlation of retinal pigment epithelium gene expression and retinal vascularization and, 692–693
      - isolation of retinal pigment epithelium and, 688, 689f, 690f, 690–691
    - lipofuscin of, 539–544, 540f, 638
    - autofluorescence of, plate 44
    - inhibiting formation of fluorophores and, targeting visual cycle for, 543f, 543–544
    - Leu450Met variant in murine Rpe65 associated with, 542–543, 543f
    - Rpe65<sup>-/-</sup> mice and, 539–540, 540f
    - Stargardt macular degeneration and *Abca4/Abcr* null mutant mice and, 540–542, 541f
    - relationship with photoreceptors, 639
    - visual cycle and, 721–722
  - Retinal progenitor cells (RPCs)
    - differentiation of, 302
    - eye field transcription factor expression in, 299, 302–303
    - Math5* activation in, 325
    - Math5* repression in, 326–327
    - proliferation of
      - control by retinal ganglion cell-secreted signaling molecules, 328–329
      - regulation of, 311
  - Retinal projections, ipsilateral and contralateral, plate 1
  - Retinal synaptic transmission, 175–184, 176f
    - control of synaptic output of bipolar cells by GABA<sub>C</sub>R-mediated inhibition and, 182–183
    - evoked response alteration of ON-center retinal ganglion cells by GABA<sub>C</sub>R-mediated inhibition and, 183–184, 184f
    - in outer retina, 175–179
      - altered, complex retinal ganglion cell phenotypes resulting from, 179
      - postsynaptic mutants and, 177t, 178–179, 179f
      - presynaptic mutants and, 177t, 177–178
    - retinal ganglion cell responses in mutants with outer plexiform layer presynaptic defects and, 179–181, 180f
    - retinal ganglion cell responses in mutants with postsynaptic defects in depolarizing bipolar cell signaling and, 181
  - Retinal vasculature, plate 45
    - degenerate capillaries in, plate 46
    - development of, 285–289, 286f, 289f
    - gene expression in
      - correlation of retinal pigment epithelium gene expression and retinal vascularization and, 692–693

- Retinal vasculature (continued)  
 isolation of retinal vasculature and subsequent gene expression studies and, 688, 689f, 691–692  
 leukocyte adherence in retinal microvasculature of diabetic mouse and, plate 47
- Retinal waves, 343–348  
 cellular mechanisms underlying, retinal development and, 343–344, 344f  
 circuits generating, functional stages of, plate 17  
 gap junctions and, 346–347  
 measurement techniques for, 343  
 mediation of, 357  
 stage I, properties of, 347, plate 18  
 stage II  
 mechanisms of, 345f, 345–346  
 properties of, plate 18  
 spatiotemporal properties of, 344–345, 345f  
 stage III, properties of, 347  
 visual circuit development and, 348, 349f
- Retinaldehyde, 364
- Retinaldehyde dehydrogenases (RALDHs), 364  
 RALDH2, 367, 367f  
 RALDH3, 367, 368f  
 colocalization with markers for neuronal plasticity, 368, 369f  
 maturation patterns in postnatal cortex defined by, 369–370, 370f  
 relationship between neurotrophin-3 and, 368–369, 369f  
 retinoic acid colocalization with sites of expression of, 365f, 365–366
- Retinitis, viral, 509
- Retinoblastoma  
 human susceptibility to, 311, 313  
 species-specific differences in susceptibility to, 313
- Retinofugal projections, of mouse compared to other mammalian species, 39t, 39–40, 40f, 41f
- Retinogenesis, early regulatory events in, 322–324
- Retinogeniculate pathway. *See also* Lateral geniculate nucleus (LGN)  
 axon segregation in, in developing mouse, plate 24  
 development of, 415–426, 425f  
 functional composition of developing pathway and, 419–420, 421f, 422  
 mechanisms underlying remodeling of connections and, 424  
 structural composition of developing pathway and, 418–419
- Retinohypothalamic tract (RHT), circadian photoentrainment and, 209–210
- Retinoic acid (RA), 363–374  
 actions in brain, 364–365  
 data bank searches and, 370–372  
 Allen Brain Atlas, 370–371, 371f  
 Brain Gene Expression Map, 370  
 evaluation of, 372  
 dorsal telencephalon function and, 366–367  
 dorsal visual stream and, 373f, 373–374  
 photoreceptor development and, 304, 305  
 RALDH2 and, 367, 367f  
 RALDH3 and, 367, 368f  
 colocalization with markers for neuronal plasticity, 368, 369f  
 maturation patterns in postnatal cortex defined by, 369–370, 370f  
 relationship between neurotrophin-3 and, 368–369, 369f  
 reporter mice and, 365f, 365–366  
 retinoid system and, 364
- Retinoid flow in visual cycle, in visual cycle, 726–727
- 11-*cis*-Retinol dehydrogenase, in visual cycle, 725
- Retinol-binding protein, in visual cycle, 725
- Retinopathy  
 of detachment, oxygen to relieve, 564  
 diabetic. *See* Diabetic retinopathy  
 oxygen-induced, 553–554  
 of prematurity (ROP), 285–294, 642  
 mouse model for study of, 285, 289  
 scoring system for, 291
- Retinopathy scoring system, 291
- Retinorecipient nuclei, of mouse compared to other mammalian species, 40–45
- Retinoscopy, streak, 75
- RF/J strain, hearing and visual abilities in, 16
- Rgr*<sup>-/-</sup> mice, 724, 725
- Rhodopsin gene, 63
- Rhodopsin gene mutations, 651
- RIIS/J strain, tactile sensitivity in, 24
- Rlbp*<sup>-/-</sup> mice, 726
- RNAi, inducible, in retina, plate 62
- Rod(s). *See also* Photoreceptors  
 bipolar cells of, ON and OFF pathway segregation and, 354  
 development of, Rb and, 313–317, 315f, 316f  
 dysfunction of, cone damage due to, 566  
 gap junctions of, 167  
 GFP expression in, plate 63  
 of mouse compared to other mammalian species, 36  
 scaling of, 263  
 spatial vision and, 81–82
- Rod monochromatism, gene replacement therapy for, 612–613
- Rod pathways, proximal, gap junctions in, 167–169, 168f
- Rod visual cycle. *See* Visual cycle, rod
- Roscoe B. Jackson Memorial Laboratory, 13
- Rpe65, Leu450Met variant in, reduced levels of retinal pigment epithelial lipofuscin associated with, 542–543, 543f
- Rpe65*, photoreceptor response to light and, 574–575
- RPE65 alleles, 638–639, 639f
- Rpe65* alleles, retinal responses to light exposure and, 650–651
- Rpe65* knockout mice, as model for Leber congenital amaurosis, 611–612
- Rpe65*<sup>-/-</sup> mice, photosensitivity in, 214
- Rpe65<sup>-/-</sup> mice, retinal pigment epithelium lipofuscin in, 539–540, 540f
- Rpgrip* knockout mice, as model for Leber congenital amaurosis, 612
- Rpgrip 1* mutations, 650
- RPR65, 637  
 isomerohydrolase reaction and, 723–724
- Rupture of lens cataract, 501
- Rx, as eye field transcription factor, 299–300
- Rx-Cre* transgenic mice, 274
- RXR- $\tau$ , opsins and, 305
- Rx/rax* homeobox transcription factor, 269

## S

- Saccade(s), 87, 88, 99
- Saccade-like rapid eye movements (SLREMs), 233  
 electrically induced, in mice, 235–238, 237f  
 measurement of, 233–234, 234f  
 spontaneous, in mice, 234f, 234–235, 236f
- Saccadic eye movements, 233–242  
 study methods for, 233  
 superior colliculus and, 233. *See also* Superior colliculus (SC)
- SB strain, mutation and effect in, 62t
- Scaling, of eye and cortex, 263–264
- Schematic eye modeling, 73–74, 74f
- Schlemm's canal  
 aqueous humor outflow and, 131  
 inner wall cells of, 132, 132f
- Scotopic signal transmission, of mouse compared to other mammalian species, 36f, 36–37
- Scotopic threshold response (STR), pattern electroretinography and, 124
- Second messengers, retinal ganglion cell axon growth ability and, 408
- Self-complementary AAV vectors (scAAV), 613–614
- Senescence-accelerated mouse (SAM), 500
- Senile cataracts, mouse models for, 500
- Sequential model of evolution, 6–7, 7f
- Serial analysis of gene expression (SAGE), 662, 663, 687
- Severe combined immunodeficiency (SCID), 506
- Shh*, control of retinal progenitor cell proliferation by, 328
- SHIRPA test battery, 30
- Shrew mice, 3–5, 8
- Single-cell recordings, cones and, 139, 140f–142f
- Single-unit recordings, for ocular dominance plasticity assessment, 439
- Sinusoidal stimuli, optokinetic reflex gain in response to, 91
- Sip 1*, lens development and, 277
- Sip1*, in cornea and lens development, 701
- Site-specific recombination, Cre-lox recombinase system for study of, 599–600
- Six3, in cornea and lens development, 700
- Six homeodomain genes, as eye field transcription factors, 300

- SJL/J strain  
 anxiety-related behavior tasks and, 29  
 conditioned taste aversion in, 29  
 cued and contextual fear conditioning in, 27  
 hearing and visual abilities in, 15t, 16  
 mutation and effect in, 62t  
 pattern discrimination in, 18  
 visual acuity of, 20
- SKH2/J strain, auditory evoked brainstem response in, 22
- Slit1*, retinal ganglion cell axon guidance through visual pathway and, 392f, 392–393
- Slit2*, retinal ganglion cell axon guidance toward optic chiasm and, 392f, 392–393
- Slit signaling, control of initial retinal ganglion cell axon outgrowth polarity in, 381–382, 382f
- Small eye artifact, 74
- Smithies, Oliver, 35
- SM/J strain  
 pattern discrimination in, 18  
 tactile sensitivity in, 24  
 taste ability in, 23  
 visual acuity of, 20
- Smooth pursuit movements, 87, 88
- Snell, George D., 13
- Sodium currents, in dorsolateral geniculate nucleus, 220, 220f
- Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), in proteomics, 713–714
- Sonic hedgehog. *See also Shh*  
 directed growth of retinal ganglion cell axons toward optic disc and, 383  
 eye field formation and, 301  
 optic nerve development and, 201
- S-opsin, cone, expression of, 136, 138–139
- Sorsby's fundus dystrophy, gene therapy for, 609–610
- Sox*, cataracts and, 494
- Sox1*, lens fiber differentiation and, 278
- Sox1*, in cornea and lens development, 701
- Sox2*  
 in cornea and lens development, 701  
 lens development and, 276
- Spacing rule, in horizontal cell mosaic, 148–150, 149f, 150f
- Spatial acuity, primary visual cortex and, 51–52
- Spatial frequency (SF) threshold, of optokinetic reflex, measurement of, 113–115, 114f, 115f
- Spatial information, retinogeniculate inputs and, 221–223, 222f–224f
- Spatial regulation, of gene expression, using cell type-specific promoters, plate 58
- Spatial resolution  
 of mouse compared to other mammalian species, 38–39  
 in mouse eye, 73
- Spatial vision  
 illuminances and, 81, 81f  
 rods and cones and, 81–82
- Spectacle lenses, refractive errors induced by, 82
- Spemann, Hans, 268
- Spiny mice, 3–4, 5, 8
- Sp1/Krüppel-like transcription factors, in cornea and lens development, 702
- Spontaneous activity, developmental, postnatal retinal ganglion cell development and, 121–122, 122f
- SPRET/Eij strain  
 hearing and visual abilities in, 15t  
 pattern discrimination in, 18  
 visual acuity of, 20
- Staggerer mutant mice, olfactory ability in, 22, 23
- Staphylococcus aureus* infections, 507–508
- Starburst amacrine cells (SACs)  
 retinal waves and, 346  
 study approaches for, 598
- Stargardt disease, 582, 723  
 in *Abca4/Abcr* null mutant mice, 540–542, 541f
- Stimulation. *See also* Environmental enrichment  
 early-life, neuronal and behavioral development and, 450–451  
 electrical, retinal ganglion cell axon growth and, 404–405  
 tactile, plasticity and, 455, 456
- Stimulus-selective response potentiation (SRP), 471–472, 472f, 473
- Strain background, 65
- Stratification patterns, Cre-lox recombinase system for study of, 601
- Stratum album intermediale (SAI), 235
- Stratum album profundum (SAP), 235
- Stratum griseum intermediale (SGI), 235  
 burst generation in, 240–241, 241f  
 cholinergic innervation of, 242
- Stratum griseum profundum (SGP), 235
- Stratum griseum superficiale (SGS), 43, 235
- Stratum opticum (SO), 43, 235
- Stratum zonale (SZ), 235
- Streak infrared, 75
- Streak retinoscopy, 75
- Streptozotocin, diabetes induced by, 548–549, 549f
- Strong, Leonell C., 13
- Sugar-induced cataracts, in mouse, 499
- Sulik, Kathleen, 270
- Superior colliculus (SC), 233  
 electrically induced saccade-like rapid eye movements and, 235–238, 237f  
 lateral geniculate nucleus synaptic remodeling and, 433–434  
 layers of, 235  
 local circuits of, 238–242  
 burst generation mechanism and, 239–241, 241f  
 cellular properties of, 238, 238f  
 GABAergic, 239  
 interlaminar connections and, 239, 240f  
 neuromodulator actions and, 241–242  
 retinal projections to, 42f, 42–44, 43f
- Superoxide dismutase, diabetic retinopathy and, 553
- Suprachiasmatic nucleus (SCN)  
 circadian photoentrainment and, 209–210, 211, 212f, 212–213  
 retinal projections to, 40, 41, 212f, 212–213
- SvEvTac. *See* 129/SvEvTac strain
- SWR/J strain, hearing and visual abilities in, 16
- Synaptic circuitry, retinal, development of, ON and OFF pathway segregation and, 354–357, 355f, 356f
- Synaptic remodeling, 429–435  
 description of, 429  
 in lateral geniculate nucleus, 430f, 430–431, 431f  
 activity and, 431–432  
 comparison with remodeling in other regions of visual system, 433–434  
 genes involved in, 434–435  
 plasticity in lateral geniculate nucleus and, 432–433  
 lateral geniculate nucleus synapses and, 429–430
- Synaptic transmission, retinal. *See* Retinal synaptic transmission
- Synaptogenesis, defects in *Rb*-deficient retinas, 317–318, 318f

## T

### T cells

- antigen-specific  
 experimental autoimmune uveitis induced by adoptive transfer of, 515  
 migration to eye, 521  
 defects in selection of repertoire of, susceptibility to experimental autoimmune uveitis and, 518  
 deficient peripheral tolerance and, susceptibility to experimental autoimmune uveitis and, 518–519  
*Pseudomonas aeruginosa* infections and, 507
- Tactile sensitivity, measurement, 24
- Tactile stimulation, plasticity and, 455, 456
- Tail flick test, 24
- TALE homeobox proteins, eye field transcription factor regulation by, 301
- Targeted ablation, to assess role of photoreceptors, 595–596
- Targeted gene manipulations, 594–595, 595f
- Targeted mutagenesis, 63, 65–66
- Taste ability, measurement of, 23–24
- Taste aversion, conditioned, 28–29
- Tau-lacZ reporter, for study of retinal ganglion cells, 599
- Taurine, photoreceptor development and, 304, 305
- Tcm* mutant, 501

- Telencephalon, dorsal, retinoic acid and, 366–367
- Temporal information, retinogeniculate inputs and, 223–225
- Temporal resolution, primary visual cortex and, 51–52
- Tetrodotoxin (TTX), lateral geniculate nucleus synaptic remodeling and, 434
- Th1, experimental autoimmune uveitis and, 520
- Th17, experimental autoimmune uveitis and, 520
- Thalamocortical relay cells (TCs)
  - calcium current of, 220
  - hyperpolarization-activated currents of, 221
  - intrinsic conductances of, modulation of, 226–227
  - potassium current of, 220–221
- Thalamus, dorsal and ventral, visual cortex connections with, 46
- Thanatins, cell death and, 337
- Thermal nociception, measurement of, 24–25
- Thy-1
  - fluorescent reporters under control of, 598
  - as retinal ganglion cell marker, 193
- Thy-1-GFP-H line, for study of retinal ganglion cells, 599
- Thymidine birth dating analysis, in retina, 302
- Thyroid hormone receptor- $\beta_2$  (*TR $\beta$ 2*), opsins and, 305
- Tilt, static, mouse response to, 92f, 92–93
- Tilt vestibulo-ocular reflex (titVOR), 92
- Tilted mice, 101
- TIMP3, gene therapy for Sorsby's fundus dystrophy using, 610
- Tissue inhibitor of matrix metalloproteinase-1, herpes simplex virus infection and, 506
- Toll-like receptors (TLRs)
  - autoimmunity triggered by, 519–520
  - infections and, 508
- Tonometry, 480
- Tono-Pen tonometer, 480
- Toxoplasma gondii* infections, 509
- Trabecular meshwork (TM), 131f, 131–132, 132f
  - in pigment dispersion syndrome, 484
  - in primary open-angle glaucoma, 484
- Transcallosal cells, binocularity and, 50–51
- Transcription factors. *See also specific factors*
  - cell death and, 338
  - in cornea and lens development, 699f, 699–703, plate 36, plate 66
    - homeobox, 699–701
    - non-homeobox, 702–703
  - photoreceptor development and, 304–305
  - retinal ganglion cell development and, 194
- Transforming growth factor  $\beta$  (TGF- $\beta$ )
  - cell death and, 336
  - retinal vascularization and, 290–291
- Transforming growth factor  $\beta_1$  (TGF- $\beta_1$ ), retinal vascularization and, 288
- Transgene insertion, 593–594, 594f
  - pathogenic effectors and, 520
  - T cell repertoire selection and, 518
- Uveoscleral outflow pathways, 132–133
- ## V
- Vacuolated lens* mutant, 500
- V-amacrine cells, 597
- Vascular cell types, 639–643, 641f, 643f
- Vascular endothelial growth factor (VEGF)
  - gene therapy for retinal neovascularization and, 609
  - herpes simplex virus infection and, 506
  - overexpression of, diabetic retinopathy and, 554
- Vascular endothelial growth factor-A (VEGF-A)
  - in angiogenesis, 640–641
  - oxygen-induced retinopathy and, 290, 291–292
  - retinal vascularization and, 286, 287
- Vascular patterning, 642
- Vascularization, 640, 641f
- Vasculogenesis, 285, 286
- Vasogenesis, blocking of, by inhaled oxygen, 563
- Vax1*, optic nerve development and, 201
- Vax1/2*, chiasm patterning and, 396
- Vegf*, control of retinal progenitor cell proliferation by, 328, 329
- Velocity storage integrator, 94–96, 95f
- Ventrolateral geniculate nucleus (vLGN), retinal projections to, 40, 41
- Vergence movements, 87, 88
- Vestibular compensation, 99
- Vestibulo-ocular reflex (VOR)
  - angular, 88–91, 89f, 90f
    - gain and response axis of, adaptation of, 96–98, 97t
    - linear, 88
    - tile (orienting), 92
    - translational, 92
    - visual, 89f, 89–90
- Vibrissae sensitivity, measurement, 24
- Vimentin, cataracts and, 498
- Viral retinitis, 509
- Virtual optokinetic reflex system, 112–113, 114f
- Virtual optokinetic system, 20
- Vision
  - lack of, environmental enrichment and, 453–455, 454f
  - in tasks evaluating higher order cognitive functions, 25
- Visual ability
  - measures of
    - of brightness/visual detection, 16, 17f, 18
    - gross, 16
    - of pattern discrimination, 17f, 18, 19f
    - of visual acuity, 18, 20, 21f
  - in mice, 15t, 16–20
- Visual acuity
  - of mouse compared to other mammalian species, 35
  - operational definition of, 108
  - of small vertebrate eyes, 73
- Transgenic mice, 14–15. *See also specific transgenic mice*
  - in gene expression analysis, 692
  - for lens research, 272–273
  - location of transgene, 65–66
  - study of amacrine cells using, 597–598
  - study of role of gap junctions in bipolar cells using, 596–597
  - temporal control of gene expression in, Cre recombinases for, 626, 627f, plate 57
  - uses of, 65
- Translational vestibulo-ocular reflex (transVOR), 92
- Traumatic optic neuropathy, retinal ganglion cell axon regeneration in, 409, 409f
- T $\alpha$ 1–3RT  $\tau$ TG mice, olfactory ability in, 22, 23
- Two-bottle test, of taste ability, 23–24
- Two-dimensional electrophoresis, in proteomics, 714–715
- Tyrosine hydroxylase (TH), primary congenital glaucoma and, 483
- Tyrl<sup>h</sup>*, pigmentary glaucoma and, 483
- ## U
- Unmyelinated region, of optic nerve, 201, 202f
- Usher's syndrome, type 1b, 584
- Uveitis, 513–523
  - endotoxin-induced, 513–515, 514f
  - experimental autoimmune uveitis, pathogenesis of, critical checkpoints in, plate 40
  - experimental autoimmune uveoretinitis, 515–517
    - associated with anti-tumor response to melanoma antigen, 517
    - histology of, plate 39
    - in human lymphocyte antigen transgenic mice, 516
    - induced by active immunization with retinal antigen, 515, 516t, 517f
    - induced by adoptive transfer of antigen-specific T cells, 515
    - induced by injection of antigen-pulsed dendritic cells, 516
    - in mice expressing a transgenic target antigen in the retina, 515–516
    - spontaneous, 516–517
  - immunotherapeutic approaches for, 522–523
  - infectious. *See* Infectious eye diseases
  - mechanisms involved in, 517–522
    - antigen presentation to lymphocytes and, 519
    - deficient peripheral tolerance as, 518–519
    - effector cell migration, infiltration, and inflammatory cell recruitment as, 521
    - innate immune signals and, 519–520
    - natural resolution mechanisms as, 521–522

- Visual behavior, correlates of ocular dominance plasticity and, 447
- Visual circuits, development of, retinal waves and, 348, 349f
- Visual cortex, 245–252
- binocular
    - mapping ocular dominance in, plate 26
    - retinotopic mapping of, plate 25
  - callosal connections of, 46–47, 47f
  - connections of, 248–251
    - areal hierarchy of, 251, 251f
    - consolidation of, environmental enrichment and, plate 29
    - between different cortical areas, 249, 250f, 251
    - with dorsal thalamus, 46
    - subcortical inputs and, 248
    - within V1, 248–249
    - with ventral thalamus and mesencephalon, 46
  - Vi, topographic maps of, plate 8
  - corticotectal cells of, physiology of, 47–48
  - cytoarchitectonic fields of, 245, 246f
  - extrastriate, in mouse compared with other mammalian species, 51–52, 52f
  - extrastriate lateromedial area intracortical connections in, plate 9, plate 10
  - interareal feedforward and feedback connections in, laminar organization of, plate 11
  - intrinsic associational corticocortical connections of, 46
  - long-range associational corticocortical connections of, 46
  - maps of, plate 7
  - of mouse compared to other mammalian species, 45–52
    - anatomy and, 45f, 45–47
    - binocularity and, 49–51, 50f
    - physiology and, 47–59, 48t
    - spatial acuity and temporal resolution and, 51–52
  - nonoriented cells of, physiology of, 47
  - orientation selectivity of, 48–49
  - relationship between cytoarchitectonic areas and topographic maps of, 248
  - topographically defined areas of, 246f, 246–248, 247f
  - visuotopic organization of, 45–46
- Visual cortical plasticity
- environmental enrichment and, 449–459
    - early-life stimulation effects on neuronal and behavioral development and, 450–451
  - neural consequences of environmental enrichment and, 450
  - visual system development and, 451–459, 452f, 454f, 455f, 457f, 459f
- experience-dependent, 465–473
- adult ocular dominance plasticity and, 472–473, 474f
  - mechanisms of ocular dominance shift in mice and, 468–471
  - monocular deprivation in juvenile mice and, 468, 469f, 470f
  - stimulus-selective response potentiation and, 471–472, 472f
  - visually evoked potential recording technique and, 466, 467f, 468
- Visual cycle, 721–729
- cone, 727, 728f, plate 69
  - inhibition of formation of retinal pigment epithelial lipofuscin fluorophores and, 543f, 543–544
  - proteomic analysis of, 727–729
    - of interacting components, 727–729
  - retinoid, 637
  - rod, genetic analysis of, 721–727, 722f, plate 68
    - all-*trans*-retinol dehydrogenase and, 722–723
    - ATP-binding cassette A4 and, 723
    - cellular retinaldehyde-binding protein and, 726
    - cellular retinol-binding protein type 1 and, 725
    - 11-*cis*-retinol dehydrogenase and, 725
    - interphotoreceptor retinoid-binding protein and, 726
    - isomerohydrolase and, 723–724
    - lecithin:retinol acyltransferase and, 723
    - retinal G protein-coupled receptor and, 724–725
    - retinoid flow in visual cycle and, 726–727
    - retinol-binding protein and RBP receptor and, 725
- Visual detection, measurement of, 16, 17f, 18
- Visual evoked potentials (VEPs)
- for ocular dominance plasticity assessment, 439–440, plate 31
  - pattern electroretinographic measurement of, 120–121, 121f
  - recording of, for assessing visual cortical plasticity, 466, 467f, 468
- Visual field, of mouse compared to other mammalian species, 39t, 39–40, 40f, 41f
- Visual function, measuring gains and losses of, behavioral methods for, 116, 116f
- Visual pathways, organization of, plate 1
- Visual phenotypes, screening of, behavioral methods for, 115–116
- Visual stimulation, ON and OFF pathway segregation and, 357–358
- Visual system
- development of
    - acceleration by environmental enrichment, plate 28
    - consolidation of visual cortical connections and, plate 29
    - environmental enrichment and, 451–459, 452f, 454f, 455f, 457f, 459f, plate 29, plate 30
    - special features in mouse affecting research, 66–67
  - Visual thalamus. *See* Lateral geniculate nucleus (LGN)
  - Visual vestibulo-ocular reflex (VVOR), 89f, 89–90
  - Visual water box, 16, 17f, 18, 20
  - Visual water task, for measuring visual perception, 110–111, 111f, 112f
  - Visual-somatosensory interaction, 24
  - Vitamin A. *See also* Retinoic acid (RA)
    - deficiency of, 364
    - excess of, 364
    - role in vision, 363
    - uptake from RBP, 725
  - Vogt-Koyanagi-Harada disease, 516
  - von Frey filament test, 24
  - Vpac2r, circadian photoentrainment and, 214
- ## W
- Water T-maze, modified, 16, 17f
- Whole-cell voltage-clamp recordings, for retinal wave measurement, 343
- Williams syndrome, visual cortical functions in, 245
- Wnt signaling, eye field transcription factor regulation by, 300–301
- Wolbachia*, 508
- ## X
- X-linked juvenile retinoschisis (XLRS), gene replacement therapy for, 611
- X-linked recessive familial exudative vitreoretinopathy (XLEVR), 528
- ## Y
- Yamamoto, Yuhiro, 270
- Yerkes apparatus, 16, 17f
- ## Z
- Zernike coefficients, 80
- Zic2
  - retinal ganglion cell axon divergence at chiasm and, 394f, 395
  - as retinal ganglion cell marker, 193
- Zonular apparatus, 129, 130f
- ZRDCT strain, 269